Trial Outcomes & Findings for Clinical Study With Blinatumomab in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL) (NCT NCT01741792)

Last Updated: 2017-01-06

Results Overview

Overall response within the first treatment cycle was assessed according to Cheson criteria by a central reader. Response was evaluated using computerized tomography (CT) scans and positron emission tomography (PET) (to assess nodal disease/organ enlargement due to nodal/diffuse infiltration), and bone marrow biopsy (to assess bone marrow infiltration). Overall objective response rate (ORR) is the percentage of participants with a best overall response of complete response (CR) or partial response (PR). Complete response is defined as the disappearance of all evidence of disease and partial response is defined as regression of measureable disease and no new sites.

Recruitment status

COMPLETED

Study phase

PHASE2

Target enrollment

25 participants

Primary outcome timeframe

During the first 8 weeks

Results posted on

2017-01-06

Participant Flow

Adults with a diagnosis of diffuse large B-cell lymphoma (DLBCL) which was refractory to first or subsequent treatment or who had a first or later relapse and were not eligible for autologous hematopoietic stem cell transplant (HSCT), or relapsed after autologous HSCT were eligible to enrol. The primary analysis cut-off date was 10 July 2014.

The study was conducted sequentially in 2 stages and 3 cohorts: In Stage 1, Cohort 1 received an escalating dose of 9/28/112 µg/day blinatumomab and Cohort 2 received a constant dose of 112 µg/day for 8 weeks. In Stage 2, the Cohort 3 dose regimen was determined from the outcome of Cohorts 1 and 2.

Participant milestones

Participant milestones
Measure	Cohort 1: Blinatumomab 9/28/112 µg/d Participants received blinatumomab administered via a continuous intravenous infusion (CIV) 9 µg/day for the first week, followed by 28 µg/day for the second week, then 112 µg/day for the remaining 6 weeks of treatment during Cycle 1. Participants who achieved a complete response (CR) or partial response (PR), or had stable disease after the first treatment cycle were eligible to receive a second (consolidation) cycle of treatment over 4 weeks, following a 4-week treatment-free interval.	Cohort 2: Blinatumomab 112 µg/d Participants received blinatumomab administered CIV at a constant dose of 112 µg/day for 8 weeks of treatment during Cycle 1. Participants who achieved a CR or PR, or had stable disease after the first treatment cycle were eligible to receive a second (consolidation) cycle of treatment over 4 weeks, following a 4-week treatment-free interval.	Cohort 3: Blinatumomab 9/28/112 µg/d Participants received blinatumomab administered CIV 9 µg/day for the first week, followed by 28 µg/day for the second week, then 112 µg/day for the remaining 6 weeks of treatment during Cycle 1. Participants who achieved CR or PR, or had stable disease after the first treatment cycle were eligible to receive a second (consolidation) cycle of treatment over 4 weeks, following a 4-week treatment-free interval.
Overall Study STARTED	9	2	14
Overall Study Efficacy Set	7	1	13
Overall Study COMPLETED	3	1	2
Overall Study NOT COMPLETED	6	1	12

Reasons for withdrawal

Reasons for withdrawal
Measure	Cohort 1: Blinatumomab 9/28/112 µg/d Participants received blinatumomab administered via a continuous intravenous infusion (CIV) 9 µg/day for the first week, followed by 28 µg/day for the second week, then 112 µg/day for the remaining 6 weeks of treatment during Cycle 1. Participants who achieved a complete response (CR) or partial response (PR), or had stable disease after the first treatment cycle were eligible to receive a second (consolidation) cycle of treatment over 4 weeks, following a 4-week treatment-free interval.	Cohort 2: Blinatumomab 112 µg/d Participants received blinatumomab administered CIV at a constant dose of 112 µg/day for 8 weeks of treatment during Cycle 1. Participants who achieved a CR or PR, or had stable disease after the first treatment cycle were eligible to receive a second (consolidation) cycle of treatment over 4 weeks, following a 4-week treatment-free interval.	Cohort 3: Blinatumomab 9/28/112 µg/d Participants received blinatumomab administered CIV 9 µg/day for the first week, followed by 28 µg/day for the second week, then 112 µg/day for the remaining 6 weeks of treatment during Cycle 1. Participants who achieved CR or PR, or had stable disease after the first treatment cycle were eligible to receive a second (consolidation) cycle of treatment over 4 weeks, following a 4-week treatment-free interval.
Overall Study Death	6	1	12

Baseline Characteristics

Clinical Study With Blinatumomab in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure	Cohort 1: Blinatumomab 9/28/112 µg/d n=9 Participants Participants received blinatumomab administered via a continuous intravenous infusion (CIV) 9 µg/day for the first week, followed by 28 µg/day for the second week, then 112 µg/day for the remaining 6 weeks of treatment during Cycle 1. Participants who achieved a complete response (CR) or partial response (PR), or had stable disease after the first treatment cycle were eligible to receive a second (consolidation) cycle of treatment over 4 weeks, following a 4-week treatment-free interval.	Cohort 2: Blinatumomab 112 µg/d n=2 Participants Participants received blinatumomab administered CIV at a constant dose of 112 µg/day for 8 weeks of treatment during Cycle 1. Participants who achieved a CR or PR, or had stable disease after the first treatment cycle were eligible to receive a second (consolidation) cycle of treatment over 4 weeks, following a 4-week treatment-free interval.	Cohort 3: Blinatumomab 9/28/112 µg/d n=14 Participants Participants received blinatumomab administered CIV 9 µg/day for the first week, followed by 28 µg/day for the second week, then 112 µg/day for the remaining 6 weeks of treatment during Cycle 1. Participants who achieved CR or PR, or had stable disease after the first treatment cycle were eligible to receive a second (consolidation) cycle of treatment over 4 weeks, following a 4-week treatment-free interval.	Total n=25 Participants Total of all reporting groups
Age, Continuous	71.7 years STANDARD_DEVIATION 7.8 • n=5 Participants	64.5 years STANDARD_DEVIATION 13.4 • n=7 Participants	57.1 years STANDARD_DEVIATION 13.6 • n=5 Participants	62.9 years STANDARD_DEVIATION 13.3 • n=4 Participants
Gender Female	7 Participants n=5 Participants	0 Participants n=7 Participants	4 Participants n=5 Participants	11 Participants n=4 Participants
Gender Male	2 Participants n=5 Participants	2 Participants n=7 Participants	10 Participants n=5 Participants	14 Participants n=4 Participants
Race/Ethnicity, Customized White	9 participants n=5 Participants	2 participants n=7 Participants	14 participants n=5 Participants	25 participants n=4 Participants
Relapsed/refractory Status to Last Prior Treatment Relapsed	4 participants n=5 Participants	1 participants n=7 Participants	4 participants n=5 Participants	9 participants n=4 Participants
Relapsed/refractory Status to Last Prior Treatment Refractory	5 participants n=5 Participants	1 participants n=7 Participants	10 participants n=5 Participants	16 participants n=4 Participants
Number of Previous Autologous Hematopoietic Stem Cell Transplants (HSCT) None	7 participants n=5 Participants	1 participants n=7 Participants	10 participants n=5 Participants	18 participants n=4 Participants
Number of Previous Autologous Hematopoietic Stem Cell Transplants (HSCT) ≥ 1	2 participants n=5 Participants	1 participants n=7 Participants	4 participants n=5 Participants	7 participants n=4 Participants

PRIMARY outcome

Timeframe: During the first 8 weeks

Population: Efficacy Set includes all participants who completed at least 7 days of infusion on the highest intended dose level.

Outcome measures

Outcome measures
Measure	Cohort 1: Blinatumomab 9/28/112 μg/d n=7 Participants Participants received blinatumomab administered via a continuous intravenous infusion (CIV) 9 µg/day for the first week, followed by 28 µg/day for the second week, then 112 µg/day for the remaining 6 weeks of treatment during Cycle 1. Participants who achieved a complete response (CR) or partial response (PR), or had stable disease after the first treatment cycle were eligible to receive a second (consolidation) cycle of treatment over 4 weeks, following a 4-week treatment-free interval.	Cohort 2: Blinatumomab 112 μg/d n=1 Participants Participants received blinatumomab CIV at a constant dose of 112 µg/day for 8 weeks of treatment during Cycle 1. Participants who achieved a CR or PR, or had stable disease after the first treatment cycle were eligible to receive a second (consolidation) cycle of treatment over 4 weeks, following a 4-week treatment-free interval.	Cohort 3: Blinatumomab 9/28/112 μg/d n=13 Participants Participants received blinatumomab administered CIV 9 µg/day for the first week, followed by 28 µg/day for the second week, then 112 µg/day for the remaining 6 weeks of treatment during Cycle 1. Participants who achieved CR or PR, or had stable disease after the first treatment cycle were eligible to receive a second (consolidation) cycle of treatment over 4 weeks, following a 4-week treatment-free interval.
Overall Objective Response Rate During Treatment Cycle 1	57.1 percentage of participants Interval 18.4 to 90.1	100.0 percentage of participants Interval 2.5 to 100.0	30.8 percentage of participants Interval 9.1 to 61.4

SECONDARY outcome

Timeframe: During the first 8 weeks

Population: Efficacy set

Response within the first treatment cycle was assessed according to Cheson criteria by a central reader. Response was evaluated using computerized tomography (CT) scans and positron emission tomography (PET) (to assess nodal disease/organ enlargement due to nodal/diffuse infiltration), and bone marrow biopsy (to assess bone marrow infiltration). Complete response is defined as the disappearance of all evidence of disease.

Outcome measures

Outcome measures
Measure	Cohort 1: Blinatumomab 9/28/112 μg/d n=7 Participants Participants received blinatumomab administered via a continuous intravenous infusion (CIV) 9 µg/day for the first week, followed by 28 µg/day for the second week, then 112 µg/day for the remaining 6 weeks of treatment during Cycle 1. Participants who achieved a complete response (CR) or partial response (PR), or had stable disease after the first treatment cycle were eligible to receive a second (consolidation) cycle of treatment over 4 weeks, following a 4-week treatment-free interval.	Cohort 2: Blinatumomab 112 μg/d n=1 Participants Participants received blinatumomab CIV at a constant dose of 112 µg/day for 8 weeks of treatment during Cycle 1. Participants who achieved a CR or PR, or had stable disease after the first treatment cycle were eligible to receive a second (consolidation) cycle of treatment over 4 weeks, following a 4-week treatment-free interval.	Cohort 3: Blinatumomab 9/28/112 μg/d n=13 Participants Participants received blinatumomab administered CIV 9 µg/day for the first week, followed by 28 µg/day for the second week, then 112 µg/day for the remaining 6 weeks of treatment during Cycle 1. Participants who achieved CR or PR, or had stable disease after the first treatment cycle were eligible to receive a second (consolidation) cycle of treatment over 4 weeks, following a 4-week treatment-free interval.
Percentage of Participants With a Best Overall Response of Complete Response	28.6 percentage of participants Interval 3.7 to 71.0	0 percentage of participants Interval 0.0 to 97.5	15.4 percentage of participants Interval 1.9 to 45.4

SECONDARY outcome

Timeframe: During the first 8 weeks

Population: Efficacy set

Response within the first treatment cycle was assessed according to Cheson criteria by a central reader. Response was evaluated using computerized tomography (CT) scans and positron emission tomography (PET) (to assess nodal disease/organ enlargement due to nodal/diffuse infiltration), and bone marrow biopsy (to assess bone marrow infiltration). Partial response is defined as regression (\<50% decrease in size of masses) of measureable disease and no new sites.

Outcome measures

Outcome measures
Measure	Cohort 1: Blinatumomab 9/28/112 μg/d n=7 Participants Participants received blinatumomab administered via a continuous intravenous infusion (CIV) 9 µg/day for the first week, followed by 28 µg/day for the second week, then 112 µg/day for the remaining 6 weeks of treatment during Cycle 1. Participants who achieved a complete response (CR) or partial response (PR), or had stable disease after the first treatment cycle were eligible to receive a second (consolidation) cycle of treatment over 4 weeks, following a 4-week treatment-free interval.	Cohort 2: Blinatumomab 112 μg/d n=1 Participants Participants received blinatumomab CIV at a constant dose of 112 µg/day for 8 weeks of treatment during Cycle 1. Participants who achieved a CR or PR, or had stable disease after the first treatment cycle were eligible to receive a second (consolidation) cycle of treatment over 4 weeks, following a 4-week treatment-free interval.	Cohort 3: Blinatumomab 9/28/112 μg/d n=13 Participants Participants received blinatumomab administered CIV 9 µg/day for the first week, followed by 28 µg/day for the second week, then 112 µg/day for the remaining 6 weeks of treatment during Cycle 1. Participants who achieved CR or PR, or had stable disease after the first treatment cycle were eligible to receive a second (consolidation) cycle of treatment over 4 weeks, following a 4-week treatment-free interval.
Percentage of Participants With a Best Overall Response of Partial Response	28.6 percentage of participants Interval 3.7 to 71.0	100.0 percentage of participants Interval 2.5 to 100.0	15.4 percentage of participants Interval 1.9 to 45.4

SECONDARY outcome

Timeframe: From first infusion of blinatumomab until the end of study; median follow-up time for duration of response was 23.7 months.

Population: Efficacy set with an overall objective response of CR or PR during the first treatment cycle

The time from documentation of the first assessment of either partial or complete response until the start of new anti-tumor treatment (excluding any stem cell transplantation), progression of disease, or death, whichever is the earliest event. A patient who did not have new anti-tumor treatment (excluding any stem cell transplantation), progression of disease, or death was censored at last tumor assessment date. Disease progression is defined as any new lesion or increase by ≥ 50% of previously involved sites from nadir.

Outcome measures

Outcome measures
Measure	Cohort 1: Blinatumomab 9/28/112 μg/d n=4 Participants Participants received blinatumomab administered via a continuous intravenous infusion (CIV) 9 µg/day for the first week, followed by 28 µg/day for the second week, then 112 µg/day for the remaining 6 weeks of treatment during Cycle 1. Participants who achieved a complete response (CR) or partial response (PR), or had stable disease after the first treatment cycle were eligible to receive a second (consolidation) cycle of treatment over 4 weeks, following a 4-week treatment-free interval.	Cohort 2: Blinatumomab 112 μg/d n=1 Participants Participants received blinatumomab CIV at a constant dose of 112 µg/day for 8 weeks of treatment during Cycle 1. Participants who achieved a CR or PR, or had stable disease after the first treatment cycle were eligible to receive a second (consolidation) cycle of treatment over 4 weeks, following a 4-week treatment-free interval.	Cohort 3: Blinatumomab 9/28/112 μg/d n=4 Participants Participants received blinatumomab administered CIV 9 µg/day for the first week, followed by 28 µg/day for the second week, then 112 µg/day for the remaining 6 weeks of treatment during Cycle 1. Participants who achieved CR or PR, or had stable disease after the first treatment cycle were eligible to receive a second (consolidation) cycle of treatment over 4 weeks, following a 4-week treatment-free interval.
Duration of Objective Response	8.7 months Interval 0.9 to Could not be estimated due to the low number of events	NA months Could not be estimated due to the low number of events	4.0 months Interval 1.9 to Could not be estimated due to the low number of events

SECONDARY outcome

Timeframe: From first infusion of blinatumomab until the end of study; median follow-up time for duration of response was 23.7 months.

Population: Efficacy set with a best overall response of CR during the first treatment cycle

The time from documentation of the first assessment of complete response until the start of new anti-tumor treatment (excluding any stem cell transplantation), progression of disease, or death, whichever is the earliest event. A patient who did not have new anti-tumor treatment (excluding any stem cell transplantation), progression of disease, or death was censored at last tumor assessment date. Disease progression is defined as any new lesion or increase by ≥ 50% of previously involved sites from nadir.

Outcome measures

Outcome measures
Measure	Cohort 1: Blinatumomab 9/28/112 μg/d n=2 Participants Participants received blinatumomab administered via a continuous intravenous infusion (CIV) 9 µg/day for the first week, followed by 28 µg/day for the second week, then 112 µg/day for the remaining 6 weeks of treatment during Cycle 1. Participants who achieved a complete response (CR) or partial response (PR), or had stable disease after the first treatment cycle were eligible to receive a second (consolidation) cycle of treatment over 4 weeks, following a 4-week treatment-free interval.	Cohort 2: Blinatumomab 112 μg/d Participants received blinatumomab CIV at a constant dose of 112 µg/day for 8 weeks of treatment during Cycle 1. Participants who achieved a CR or PR, or had stable disease after the first treatment cycle were eligible to receive a second (consolidation) cycle of treatment over 4 weeks, following a 4-week treatment-free interval.	Cohort 3: Blinatumomab 9/28/112 μg/d n=2 Participants Participants received blinatumomab administered CIV 9 µg/day for the first week, followed by 28 µg/day for the second week, then 112 µg/day for the remaining 6 weeks of treatment during Cycle 1. Participants who achieved CR or PR, or had stable disease after the first treatment cycle were eligible to receive a second (consolidation) cycle of treatment over 4 weeks, following a 4-week treatment-free interval.
Duration of Complete Response	NA months Interval 11.6 to Could not be estimated due to the low number of events	—	NA months Interval 5.9 to Could not be estimated due to the low number of events

SECONDARY outcome

Timeframe: From first infusion of blinatumomab until the end of study; median follow-up time for duration of response was 23.7 months.

Population: Efficacy set with a best overall response of PR during the first treatment cycle

The time from documentation of the first assessment of partial response until the start of new anti-tumor treatment (excluding any stem cell transplantation), progression of disease, or death, whichever is the earliest event. A patient who did not have new anti-tumor treatment (excluding any stem cell transplantation), progression of disease, or death was censored at last tumor assessment date. Disease progression is defined as any new lesion or increase by ≥ 50% of previously involved sites from nadir.

Outcome measures

Outcome measures
Measure	Cohort 1: Blinatumomab 9/28/112 μg/d n=2 Participants Participants received blinatumomab administered via a continuous intravenous infusion (CIV) 9 µg/day for the first week, followed by 28 µg/day for the second week, then 112 µg/day for the remaining 6 weeks of treatment during Cycle 1. Participants who achieved a complete response (CR) or partial response (PR), or had stable disease after the first treatment cycle were eligible to receive a second (consolidation) cycle of treatment over 4 weeks, following a 4-week treatment-free interval.	Cohort 2: Blinatumomab 112 μg/d n=1 Participants Participants received blinatumomab CIV at a constant dose of 112 µg/day for 8 weeks of treatment during Cycle 1. Participants who achieved a CR or PR, or had stable disease after the first treatment cycle were eligible to receive a second (consolidation) cycle of treatment over 4 weeks, following a 4-week treatment-free interval.	Cohort 3: Blinatumomab 9/28/112 μg/d n=2 Participants Participants received blinatumomab administered CIV 9 µg/day for the first week, followed by 28 µg/day for the second week, then 112 µg/day for the remaining 6 weeks of treatment during Cycle 1. Participants who achieved CR or PR, or had stable disease after the first treatment cycle were eligible to receive a second (consolidation) cycle of treatment over 4 weeks, following a 4-week treatment-free interval.
Duration of Partial Response	3.3 months Interval 0.9 to 5.8	NA months Could not be estimated due to the low number of events	2.0 months Interval 1.9 to 2.1

SECONDARY outcome

Timeframe: From first infusion of blinatumomab until the end of study; median time on follow-up for PFS was 27.0 months.

Population: Efficacy set

The time from the date of first blinatumomab infusion until the date of diagnosis of progression of lymphoma, the start date of new anti-tumor treatment (excluding any stem cell transplantation) or date of death, whichever is the earliest. Patients alive who did not have progression or new anti-tumor treatment (excluding any stem cell transplantation) were censored at last date of tumor assessment.

Outcome measures

Outcome measures
Measure	Cohort 1: Blinatumomab 9/28/112 μg/d n=7 Participants Participants received blinatumomab administered via a continuous intravenous infusion (CIV) 9 µg/day for the first week, followed by 28 µg/day for the second week, then 112 µg/day for the remaining 6 weeks of treatment during Cycle 1. Participants who achieved a complete response (CR) or partial response (PR), or had stable disease after the first treatment cycle were eligible to receive a second (consolidation) cycle of treatment over 4 weeks, following a 4-week treatment-free interval.	Cohort 2: Blinatumomab 112 μg/d n=1 Participants Participants received blinatumomab CIV at a constant dose of 112 µg/day for 8 weeks of treatment during Cycle 1. Participants who achieved a CR or PR, or had stable disease after the first treatment cycle were eligible to receive a second (consolidation) cycle of treatment over 4 weeks, following a 4-week treatment-free interval.	Cohort 3: Blinatumomab 9/28/112 μg/d n=13 Participants Participants received blinatumomab administered CIV 9 µg/day for the first week, followed by 28 µg/day for the second week, then 112 µg/day for the remaining 6 weeks of treatment during Cycle 1. Participants who achieved CR or PR, or had stable disease after the first treatment cycle were eligible to receive a second (consolidation) cycle of treatment over 4 weeks, following a 4-week treatment-free interval.
Progression-free Survival (PFS)	3.7 months Interval 0.7 to 14.1	NA months Could not be estimated due to the low number of events	1.6 months Interval 0.6 to 4.6

SECONDARY outcome

Timeframe: From the first infusion of blinatumomab until the end of study; median time on follow-up for overall survival was 26.6 months.

Population: Efficacy set

The time from the date of first blinatumomab infusion until death as a result of any cause. Patients still alive were censored on the last documented visit date or the date of the last phone contact when the patient was last known to have been alive. For patients who withdrew their informed consent, only information until the date of withdrawal was analyzed.

Outcome measures

Outcome measures
Measure	Cohort 1: Blinatumomab 9/28/112 μg/d n=7 Participants Participants received blinatumomab administered via a continuous intravenous infusion (CIV) 9 µg/day for the first week, followed by 28 µg/day for the second week, then 112 µg/day for the remaining 6 weeks of treatment during Cycle 1. Participants who achieved a complete response (CR) or partial response (PR), or had stable disease after the first treatment cycle were eligible to receive a second (consolidation) cycle of treatment over 4 weeks, following a 4-week treatment-free interval.	Cohort 2: Blinatumomab 112 μg/d n=1 Participants Participants received blinatumomab CIV at a constant dose of 112 µg/day for 8 weeks of treatment during Cycle 1. Participants who achieved a CR or PR, or had stable disease after the first treatment cycle were eligible to receive a second (consolidation) cycle of treatment over 4 weeks, following a 4-week treatment-free interval.	Cohort 3: Blinatumomab 9/28/112 μg/d n=13 Participants Participants received blinatumomab administered CIV 9 µg/day for the first week, followed by 28 µg/day for the second week, then 112 µg/day for the remaining 6 weeks of treatment during Cycle 1. Participants who achieved CR or PR, or had stable disease after the first treatment cycle were eligible to receive a second (consolidation) cycle of treatment over 4 weeks, following a 4-week treatment-free interval.
Overall Survival (OS)	20.1 months Interval 2.3 to Could not be estimated due to the low number of events	NA months Could not be estimated due to the low number of events	3.6 months Interval 1.5 to 14.8

SECONDARY outcome

Timeframe: From the first dose of blinatumomab until up to 30 days after the last dose or until the data cut-off date of 10 July 2014, whichever occurred first; the overall median duration of treatment exposure was 46.8 days.

Population: Safety analysis set

Adverse events were evaluated for severity according to the grading scale provided in the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE), version 4.0. An adverse event or suspected adverse drug reaction was considered "serious" if it resulted in one of the following outcomes: * Resulted in death; * Was life-threatening; * Required inpatient hospitalization or prolongation of existing hospitalization; * Resulted in persistent or significant incapacity or substantial disruption to conduct normal life functions; * Was a congenital anomaly or birth defect; * Was a medically important condition. The Investigator used medical judgment to determine whether there was a causal relationship (ie, related \[reasonably possible\] or unrelated \[not reasonably possible\]) between an adverse event and blinatumomab.

Outcome measures

Outcome measures
Measure	Cohort 1: Blinatumomab 9/28/112 μg/d n=9 Participants Participants received blinatumomab administered via a continuous intravenous infusion (CIV) 9 µg/day for the first week, followed by 28 µg/day for the second week, then 112 µg/day for the remaining 6 weeks of treatment during Cycle 1. Participants who achieved a complete response (CR) or partial response (PR), or had stable disease after the first treatment cycle were eligible to receive a second (consolidation) cycle of treatment over 4 weeks, following a 4-week treatment-free interval.	Cohort 2: Blinatumomab 112 μg/d n=2 Participants Participants received blinatumomab CIV at a constant dose of 112 µg/day for 8 weeks of treatment during Cycle 1. Participants who achieved a CR or PR, or had stable disease after the first treatment cycle were eligible to receive a second (consolidation) cycle of treatment over 4 weeks, following a 4-week treatment-free interval.	Cohort 3: Blinatumomab 9/28/112 μg/d n=14 Participants Participants received blinatumomab administered CIV 9 µg/day for the first week, followed by 28 µg/day for the second week, then 112 µg/day for the remaining 6 weeks of treatment during Cycle 1. Participants who achieved CR or PR, or had stable disease after the first treatment cycle were eligible to receive a second (consolidation) cycle of treatment over 4 weeks, following a 4-week treatment-free interval.
Number of Participants With Adverse Events Any adverse event (AE)	9 participants	2 participants	14 participants
Number of Participants With Adverse Events AE of Grade ≥ 3	9 participants	2 participants	13 participants
Number of Participants With Adverse Events Serious adverse event (SAE)	9 participants	2 participants	12 participants
Number of Participants With Adverse Events Fatal adverse events	0 participants	0 participants	2 participants
Number of Participants With Adverse Events Led to interruption of study drug	4 participants	1 participants	6 participants
Number of Participants With Adverse Events Related adverse events	9 participants	2 participants	11 participants
Number of Participants With Adverse Events Related AE Grade ≥ 3	5 participants	2 participants	5 participants
Number of Participants With Adverse Events Related AE Grade ≥ 4	0 participants	1 participants	2 participants
Number of Participants With Adverse Events Serious related adverse events	5 participants	2 participants	3 participants
Number of Participants With Adverse Events Related AE led to discontinuation of study drug	2 participants	1 participants	2 participants
Number of Participants With Adverse Events Related AE led to interruption of study drug	3 participants	1 participants	3 participants
Number of Participants With Adverse Events AE of Grade ≥ 4	0 participants	2 participants	6 participants
Number of Participants With Adverse Events Led to discontinuation of study drug	3 participants	1 participants	2 participants

SECONDARY outcome

Timeframe: Cycle 1: predose; Day 3 and Day 8 (Css for 9 ug/day); Day 15 (Css for 28 ug/day); and Day 29, Day 43 and Day 57 (Css for 112 ug/day)

Population: Pharmacokinetic (PK) data set (all participants who received any infusion of blinatumomab and had at least one PK sample collected).

Blinatumomab serum levels were analyzed using a validated cluster of differentiation (CD)69 activation bioassay with a lower limit of quantification (LLOQ) of 50 pg/mL. Steady-state concentration (Css) was based on actual dose received, rather than based on cohort or time or day.

Outcome measures

Outcome measures
Measure	Cohort 1: Blinatumomab 9/28/112 μg/d n=20 Participants Participants received blinatumomab administered via a continuous intravenous infusion (CIV) 9 µg/day for the first week, followed by 28 µg/day for the second week, then 112 µg/day for the remaining 6 weeks of treatment during Cycle 1. Participants who achieved a complete response (CR) or partial response (PR), or had stable disease after the first treatment cycle were eligible to receive a second (consolidation) cycle of treatment over 4 weeks, following a 4-week treatment-free interval.	Cohort 2: Blinatumomab 112 μg/d n=16 Participants Participants received blinatumomab CIV at a constant dose of 112 µg/day for 8 weeks of treatment during Cycle 1. Participants who achieved a CR or PR, or had stable disease after the first treatment cycle were eligible to receive a second (consolidation) cycle of treatment over 4 weeks, following a 4-week treatment-free interval.	Cohort 3: Blinatumomab 9/28/112 μg/d n=12 Participants Participants received blinatumomab administered CIV 9 µg/day for the first week, followed by 28 µg/day for the second week, then 112 µg/day for the remaining 6 weeks of treatment during Cycle 1. Participants who achieved CR or PR, or had stable disease after the first treatment cycle were eligible to receive a second (consolidation) cycle of treatment over 4 weeks, following a 4-week treatment-free interval.
Blinatumomab Steady State Serum Concentration	277 pg/mL Standard Deviation 210	565 pg/mL Standard Deviation 208	2800 pg/mL Standard Deviation 1150

SECONDARY outcome

Timeframe: Screening (Day -20 to Day 0), Day 1 pre-infusion, Days 8, 15, 29, 43, end of infusion (day 53), end of core study (day 87), and follow-up at 3, 6, 9, 12, 15, 18, 21 and 24 months after the first response assessment

Population: Enrolled participants with available data at each time point. All participants are included in pre-infusion and follow-up data points, only those participants in Cohorts 1 and 3 who had the same treatment schedule of 9/28/112 µg/day step dosing are included in the infusion time points (day 8 through end of infusion).

Leukocyte (white blood cells) counts were analyzed by differential blood count analysis.

Outcome measures

Outcome measures
Measure	Cohort 1: Blinatumomab 9/28/112 μg/d n=25 Participants Participants received blinatumomab administered via a continuous intravenous infusion (CIV) 9 µg/day for the first week, followed by 28 µg/day for the second week, then 112 µg/day for the remaining 6 weeks of treatment during Cycle 1. Participants who achieved a complete response (CR) or partial response (PR), or had stable disease after the first treatment cycle were eligible to receive a second (consolidation) cycle of treatment over 4 weeks, following a 4-week treatment-free interval.	Cohort 2: Blinatumomab 112 μg/d Participants received blinatumomab CIV at a constant dose of 112 µg/day for 8 weeks of treatment during Cycle 1. Participants who achieved a CR or PR, or had stable disease after the first treatment cycle were eligible to receive a second (consolidation) cycle of treatment over 4 weeks, following a 4-week treatment-free interval.	Cohort 3: Blinatumomab 9/28/112 μg/d Participants received blinatumomab administered CIV 9 µg/day for the first week, followed by 28 µg/day for the second week, then 112 µg/day for the remaining 6 weeks of treatment during Cycle 1. Participants who achieved CR or PR, or had stable disease after the first treatment cycle were eligible to receive a second (consolidation) cycle of treatment over 4 weeks, following a 4-week treatment-free interval.
Leukocyte Counts Screening (N = 25)	6.376 1000 cells/µL Standard Deviation 3.284	—	—
Leukocyte Counts Day 1 Prior (N = 24)	5.729 1000 cells/µL Standard Deviation 2.891	—	—
Leukocyte Counts Day 29 (N = 11)	3.764 1000 cells/µL Standard Deviation 2.160	—	—
Leukocyte Counts Day 43 (N = 8)	4.950 1000 cells/µL Standard Deviation 3.819	—	—
Leukocyte Counts End of Infusion (N = 9)	4.611 1000 cells/µL Standard Deviation 2.114	—	—
Leukocyte Counts End of Core Study (N = 6)	6.850 1000 cells/µL Standard Deviation 2.818	—	—
Leukocyte Counts 3-Month Follow-up (N = 5)	4.820 1000 cells/µL Standard Deviation 1.616	—	—
Leukocyte Counts 6-Month Follow-up (N = 6)	5.183 1000 cells/µL Standard Deviation 1.380	—	—
Leukocyte Counts 9-Month Follow-up (N = 4)	4.425 1000 cells/µL Standard Deviation 0.854	—	—
Leukocyte Counts 12-Month Follow-up (N = 4)	5.700 1000 cells/µL Standard Deviation 1.424	—	—
Leukocyte Counts 15-Month Follow-up (N = 3)	4.767 1000 cells/µL Standard Deviation 0.874	—	—
Leukocyte Counts 18-Month Follow-up (N = 3)	6.467 1000 cells/µL Standard Deviation 1.779	—	—
Leukocyte Counts 21-Month Follow-up (N = 21)	5.450 1000 cells/µL Standard Deviation 0.495	—	—
Leukocyte Counts 24-Month Follow-up (N = 3)	4.533 1000 cells/µL Standard Deviation 1.069	—	—
Leukocyte Counts Day 8 (N = 21)	6.819 1000 cells/µL Standard Deviation 3.201	—	—
Leukocyte Counts Day 15 (N = 16)	6.400 1000 cells/µL Standard Deviation 2.486	—	—

SECONDARY outcome

Lymphocyte counts were analyzed by differential blood count analysis.

Outcome measures

Outcome measures
Measure	Cohort 1: Blinatumomab 9/28/112 μg/d n=25 Participants Participants received blinatumomab administered via a continuous intravenous infusion (CIV) 9 µg/day for the first week, followed by 28 µg/day for the second week, then 112 µg/day for the remaining 6 weeks of treatment during Cycle 1. Participants who achieved a complete response (CR) or partial response (PR), or had stable disease after the first treatment cycle were eligible to receive a second (consolidation) cycle of treatment over 4 weeks, following a 4-week treatment-free interval.	Cohort 2: Blinatumomab 112 μg/d Participants received blinatumomab CIV at a constant dose of 112 µg/day for 8 weeks of treatment during Cycle 1. Participants who achieved a CR or PR, or had stable disease after the first treatment cycle were eligible to receive a second (consolidation) cycle of treatment over 4 weeks, following a 4-week treatment-free interval.	Cohort 3: Blinatumomab 9/28/112 μg/d Participants received blinatumomab administered CIV 9 µg/day for the first week, followed by 28 µg/day for the second week, then 112 µg/day for the remaining 6 weeks of treatment during Cycle 1. Participants who achieved CR or PR, or had stable disease after the first treatment cycle were eligible to receive a second (consolidation) cycle of treatment over 4 weeks, following a 4-week treatment-free interval.
Lymphocyte Counts Screening (N = 25)	0.779 1000 cells/µL Standard Deviation 0.425	—	—
Lymphocyte Counts Day 1 Prior (N = 24)	0.491 1000 cells/µL Standard Deviation 0.259	—	—
Lymphocyte Counts Day 8 (N = 21)	0.382 1000 cells/µL Standard Deviation 0.215	—	—
Lymphocyte Counts Day 15 (N = 16)	0.277 1000 cells/µL Standard Deviation 0.165	—	—
Lymphocyte Counts Day 29 (N = 11)	0.472 1000 cells/µL Standard Deviation 0.273	—	—
Lymphocyte Counts Day 43 (N = 8)	0.847 1000 cells/µL Standard Deviation 0.511	—	—
Lymphocyte Counts End of Infusion (N = 9)	0.767 1000 cells/µL Standard Deviation 0.505	—	—
Lymphocyte Counts 12-Month Follow-up (N = 4)	1.120 1000 cells/µL Standard Deviation 0.449	—	—
Lymphocyte Counts 15-Month Follow-up (N = 3)	0.998 1000 cells/µL Standard Deviation 0.527	—	—
Lymphocyte Counts 18-Month Follow-up (N = 3)	0.565 1000 cells/µL Standard Deviation 0.180	—	—
Lymphocyte Counts 21-Month Follow-up (N = 21)	1.205 1000 cells/µL Standard Deviation 0.839	—	—
Lymphocyte Counts 24-Month Follow-up (N = 3)	0.737 1000 cells/µL Standard Deviation 0.478	—	—
Lymphocyte Counts End of Core Study (N = 6)	1.060 1000 cells/µL Standard Deviation 0.489	—	—
Lymphocyte Counts 3-Month Follow-up (N = 5)	1.053 1000 cells/µL Standard Deviation 0.421	—	—
Lymphocyte Counts 6-Month Follow-up (N = 6)	1.120 1000 cells/µL Standard Deviation 0.621	—	—
Lymphocyte Counts 9-Month Follow-up (N = 4)	1.048 1000 cells/µL Standard Deviation 0.381	—	—

SECONDARY outcome

Outcome measures

Outcome measures
Measure	Cohort 1: Blinatumomab 9/28/112 μg/d n=25 Participants Participants received blinatumomab administered via a continuous intravenous infusion (CIV) 9 µg/day for the first week, followed by 28 µg/day for the second week, then 112 µg/day for the remaining 6 weeks of treatment during Cycle 1. Participants who achieved a complete response (CR) or partial response (PR), or had stable disease after the first treatment cycle were eligible to receive a second (consolidation) cycle of treatment over 4 weeks, following a 4-week treatment-free interval.	Cohort 2: Blinatumomab 112 μg/d Participants received blinatumomab CIV at a constant dose of 112 µg/day for 8 weeks of treatment during Cycle 1. Participants who achieved a CR or PR, or had stable disease after the first treatment cycle were eligible to receive a second (consolidation) cycle of treatment over 4 weeks, following a 4-week treatment-free interval.	Cohort 3: Blinatumomab 9/28/112 μg/d Participants received blinatumomab administered CIV 9 µg/day for the first week, followed by 28 µg/day for the second week, then 112 µg/day for the remaining 6 weeks of treatment during Cycle 1. Participants who achieved CR or PR, or had stable disease after the first treatment cycle were eligible to receive a second (consolidation) cycle of treatment over 4 weeks, following a 4-week treatment-free interval.
Monocyte Counts Screening (N = 25)	0.638 1000 cells/µL Standard Deviation 0.415	—	—
Monocyte Counts Day 1 Prior (N = 24)	0.300 1000 cells/µL Standard Deviation 0.565	—	—
Monocyte Counts Day 8 (N = 21)	0.202 1000 cells/µL Standard Deviation 0.386	—	—
Monocyte Counts Day 15 (N = 16)	0.188 1000 cells/µL Standard Deviation 0.317	—	—
Monocyte Counts Day 29 (N = 11)	0.318 1000 cells/µL Standard Deviation 0.185	—	—
Monocyte Counts Day 43 (N = 8)	0.646 1000 cells/µL Standard Deviation 0.375	—	—
Monocyte Counts End of Infusion (N = 9)	0.473 1000 cells/µL Standard Deviation 0.241	—	—
Monocyte Counts End of Core Study (N = 6)	0.711 1000 cells/µL Standard Deviation 0.569	—	—
Monocyte Counts 3-Month Follow-up (N = 5)	0.585 1000 cells/µL Standard Deviation 0.280	—	—
Monocyte Counts 6-Month Follow-up (N = 6)	0.487 1000 cells/µL Standard Deviation 0.239	—	—
Monocyte Counts 9-Month Follow-up (N = 4)	0.452 1000 cells/µL Standard Deviation 0.112	—	—
Monocyte Counts 12-Month Follow-up (N = 4)	0.469 1000 cells/µL Standard Deviation 0.061	—	—
Monocyte Counts 15-Month Follow-up (N = 3)	0.511 1000 cells/µL Standard Deviation 0.053	—	—
Monocyte Counts 18-Month Follow-up (N = 3)	0.290 1000 cells/µL Standard Deviation 0.123	—	—
Monocyte Counts 21-Month Follow-up (N = 21)	0.516 1000 cells/µL Standard Deviation 0.008	—	—
Monocyte Counts 24-Month Follow-up (N = 3)	0.234 1000 cells/µL Standard Deviation 0.176	—	—

SECONDARY outcome

Outcome measures

Outcome measures
Measure	Cohort 1: Blinatumomab 9/28/112 μg/d n=25 Participants Participants received blinatumomab administered via a continuous intravenous infusion (CIV) 9 µg/day for the first week, followed by 28 µg/day for the second week, then 112 µg/day for the remaining 6 weeks of treatment during Cycle 1. Participants who achieved a complete response (CR) or partial response (PR), or had stable disease after the first treatment cycle were eligible to receive a second (consolidation) cycle of treatment over 4 weeks, following a 4-week treatment-free interval.	Cohort 2: Blinatumomab 112 μg/d Participants received blinatumomab CIV at a constant dose of 112 µg/day for 8 weeks of treatment during Cycle 1. Participants who achieved a CR or PR, or had stable disease after the first treatment cycle were eligible to receive a second (consolidation) cycle of treatment over 4 weeks, following a 4-week treatment-free interval.	Cohort 3: Blinatumomab 9/28/112 μg/d Participants received blinatumomab administered CIV 9 µg/day for the first week, followed by 28 µg/day for the second week, then 112 µg/day for the remaining 6 weeks of treatment during Cycle 1. Participants who achieved CR or PR, or had stable disease after the first treatment cycle were eligible to receive a second (consolidation) cycle of treatment over 4 weeks, following a 4-week treatment-free interval.
Granulocyte Count Screening (N = 25)	4.968 1000 cells/µL Standard Deviation 3.187	—	—
Granulocyte Count Day 1 Prior (N = 24)	4.910 1000 cells/µL Standard Deviation 2.425	—	—
Granulocyte Count Day 8 (N = 21)	6.235 1000 cells/µL Standard Deviation 2.881	—	—
Granulocyte Count Day 15 (N = 16)	5.935 1000 cells/µL Standard Deviation 2.387	—	—
Granulocyte Count Day 29 (N = 11)	2.974 1000 cells/µL Standard Deviation 2.019	—	—
Granulocyte Count Day 43 (N = 8)	3.457 1000 cells/µL Standard Deviation 3.395	—	—
Granulocyte Count End of Infusion (N = 9)	3.353 1000 cells/µL Standard Deviation 2.134	—	—
Granulocyte Count End of Core Study (N = 6)	5.080 1000 cells/µL Standard Deviation 3.012	—	—
Granulocyte Count 3-Month Follow-up (N = 5)	3.182 1000 cells/µL Standard Deviation 1.117	—	—
Granulocyte Count 6-Month Follow-up (N = 6)	3.594 1000 cells/µL Standard Deviation 0.950	—	—
Granulocyte Count 9-Month Follow-up (N = 4)	2.925 1000 cells/µL Standard Deviation 0.675	—	—
Granulocyte Count 12-Month Follow-up (N = 4)	4.111 1000 cells/µL Standard Deviation 1.382	—	—
Granulocyte Count 15-Month Follow-up (N = 3)	3.258 1000 cells/µL Standard Deviation 0.745	—	—
Granulocyte Count 18-Month Follow-up (N = 3)	5.612 1000 cells/µL Standard Deviation 1.713	—	—
Granulocyte Count 21-Month Follow-up (N = 21)	3.729 1000 cells/µL Standard Deviation 0.352	—	—
Granulocyte Count 24-Month Follow-up (N = 3)	3.563 1000 cells/µL Standard Deviation 0.711	—	—

SECONDARY outcome

CD19+ B-cell counts were analyzed by flow cytometry.

Outcome measures

Outcome measures
Measure	Cohort 1: Blinatumomab 9/28/112 μg/d n=25 Participants Participants received blinatumomab administered via a continuous intravenous infusion (CIV) 9 µg/day for the first week, followed by 28 µg/day for the second week, then 112 µg/day for the remaining 6 weeks of treatment during Cycle 1. Participants who achieved a complete response (CR) or partial response (PR), or had stable disease after the first treatment cycle were eligible to receive a second (consolidation) cycle of treatment over 4 weeks, following a 4-week treatment-free interval.	Cohort 2: Blinatumomab 112 μg/d Participants received blinatumomab CIV at a constant dose of 112 µg/day for 8 weeks of treatment during Cycle 1. Participants who achieved a CR or PR, or had stable disease after the first treatment cycle were eligible to receive a second (consolidation) cycle of treatment over 4 weeks, following a 4-week treatment-free interval.	Cohort 3: Blinatumomab 9/28/112 μg/d Participants received blinatumomab administered CIV 9 µg/day for the first week, followed by 28 µg/day for the second week, then 112 µg/day for the remaining 6 weeks of treatment during Cycle 1. Participants who achieved CR or PR, or had stable disease after the first treatment cycle were eligible to receive a second (consolidation) cycle of treatment over 4 weeks, following a 4-week treatment-free interval.
CD19+ B-Cell Count Day 15 (N = 16)	0.000 1000 cells/µL Standard Deviation 0.001	—	—
CD19+ B-Cell Count Day 29 (N = 11)	0.000 1000 cells/µL Standard Deviation 0.000	—	—
CD19+ B-Cell Count Day 43 (N = 8)	0.000 1000 cells/µL Standard Deviation 0.001	—	—
CD19+ B-Cell Count End of Infusion (N = 9)	0.001 1000 cells/µL Standard Deviation 0.001	—	—
CD19+ B-Cell Count End of Core Study (N = 6)	0.001 1000 cells/µL Standard Deviation 0.002	—	—
CD19+ B-Cell Count 3-Month Follow-up (N = 5)	0.025 1000 cells/µL Standard Deviation 0.026	—	—
CD19+ B-Cell Count 6-Month Follow-up (N = 6)	0.029 1000 cells/µL Standard Deviation 0.043	—	—
CD19+ B-Cell Count 9-Month Follow-up (N = 4)	0.054 1000 cells/µL Standard Deviation 0.066	—	—
CD19+ B-Cell Count 12-Month Follow-up (N = 4)	0.082 1000 cells/µL Standard Deviation 0.113	—	—
CD19+ B-Cell Count 15-Month Follow-up (N = 3)	0.094 1000 cells/µL Standard Deviation 0.118	—	—
CD19+ B-Cell Count 18-Month Follow-up (N = 3)	0.071 1000 cells/µL Standard Deviation 0.075	—	—
CD19+ B-Cell Count 21-Month Follow-up (N = 21)	0.131 1000 cells/µL Standard Deviation 0.170	—	—
CD19+ B-Cell Count 24-Month Follow-up (N = 3)	0.108 1000 cells/µL Standard Deviation 0.120	—	—
CD19+ B-Cell Count Screening (N = 25)	0.026 1000 cells/µL Standard Deviation 0.072	—	—
CD19+ B-Cell Count Day 1 Prior (N = 24)	0.029 1000 cells/µL Standard Deviation 0.085	—	—
CD19+ B-Cell Count Day 8 (N = 21)	0.001 1000 cells/µL Standard Deviation 0.002	—	—

SECONDARY outcome

CD19+ B-cell counts were analyzed by flow cytometry.

Outcome measures

Outcome measures
Measure	Cohort 1: Blinatumomab 9/28/112 μg/d n=25 Participants Participants received blinatumomab administered via a continuous intravenous infusion (CIV) 9 µg/day for the first week, followed by 28 µg/day for the second week, then 112 µg/day for the remaining 6 weeks of treatment during Cycle 1. Participants who achieved a complete response (CR) or partial response (PR), or had stable disease after the first treatment cycle were eligible to receive a second (consolidation) cycle of treatment over 4 weeks, following a 4-week treatment-free interval.	Cohort 2: Blinatumomab 112 μg/d Participants received blinatumomab CIV at a constant dose of 112 µg/day for 8 weeks of treatment during Cycle 1. Participants who achieved a CR or PR, or had stable disease after the first treatment cycle were eligible to receive a second (consolidation) cycle of treatment over 4 weeks, following a 4-week treatment-free interval.	Cohort 3: Blinatumomab 9/28/112 μg/d Participants received blinatumomab administered CIV 9 µg/day for the first week, followed by 28 µg/day for the second week, then 112 µg/day for the remaining 6 weeks of treatment during Cycle 1. Participants who achieved CR or PR, or had stable disease after the first treatment cycle were eligible to receive a second (consolidation) cycle of treatment over 4 weeks, following a 4-week treatment-free interval.
CD19+ B-Cells as a Percentage of All Lymphocytes Screening (N = 25)	2 percentage of lymphocytes Standard Deviation 7	—	—
CD19+ B-Cells as a Percentage of All Lymphocytes Day 1 Prior (N = 24)	4 percentage of lymphocytes Standard Deviation 9	—	—
CD19+ B-Cells as a Percentage of All Lymphocytes Day 8 (N = 21)	0 percentage of lymphocytes Standard Deviation 0	—	—
CD19+ B-Cells as a Percentage of All Lymphocytes Day 15 (N = 16)	0 percentage of lymphocytes Standard Deviation 0	—	—
CD19+ B-Cells as a Percentage of All Lymphocytes Day 29 (N = 11)	0 percentage of lymphocytes Standard Deviation 0	—	—
CD19+ B-Cells as a Percentage of All Lymphocytes Day 43 (N = 8)	0 percentage of lymphocytes Standard Deviation 0	—	—
CD19+ B-Cells as a Percentage of All Lymphocytes End of Infusion (N = 9)	0 percentage of lymphocytes Standard Deviation 0	—	—
CD19+ B-Cells as a Percentage of All Lymphocytes End of Core Study (N = 6)	0 percentage of lymphocytes Standard Deviation 0	—	—
CD19+ B-Cells as a Percentage of All Lymphocytes 3-Month Follow-up (N = 5)	2 percentage of lymphocytes Standard Deviation 2	—	—
CD19+ B-Cells as a Percentage of All Lymphocytes 6-Month Follow-up (N = 6)	2 percentage of lymphocytes Standard Deviation 3	—	—
CD19+ B-Cells as a Percentage of All Lymphocytes 9-Month Follow-up (N = 4)	5 percentage of lymphocytes Standard Deviation 5	—	—
CD19+ B-Cells as a Percentage of All Lymphocytes 12-Month Follow-up (N = 4)	7 percentage of lymphocytes Standard Deviation 9	—	—
CD19+ B-Cells as a Percentage of All Lymphocytes 15-Month Follow-up (N = 3)	7 percentage of lymphocytes Standard Deviation 7	—	—
CD19+ B-Cells as a Percentage of All Lymphocytes 18-Month Follow-up (N = 3)	11 percentage of lymphocytes Standard Deviation 9	—	—
CD19+ B-Cells as a Percentage of All Lymphocytes 21-Month Follow-up (N = 21)	8 percentage of lymphocytes Standard Deviation 8	—	—
CD19+ B-Cells as a Percentage of All Lymphocytes 24-Month Follow-up (N = 3)	12 percentage of lymphocytes Standard Deviation 7	—	—

SECONDARY outcome

CD3+ T-cell counts were analyzed by flow cytometry.

Outcome measures

Outcome measures
Measure	Cohort 1: Blinatumomab 9/28/112 μg/d n=25 Participants Participants received blinatumomab administered via a continuous intravenous infusion (CIV) 9 µg/day for the first week, followed by 28 µg/day for the second week, then 112 µg/day for the remaining 6 weeks of treatment during Cycle 1. Participants who achieved a complete response (CR) or partial response (PR), or had stable disease after the first treatment cycle were eligible to receive a second (consolidation) cycle of treatment over 4 weeks, following a 4-week treatment-free interval.	Cohort 2: Blinatumomab 112 μg/d Participants received blinatumomab CIV at a constant dose of 112 µg/day for 8 weeks of treatment during Cycle 1. Participants who achieved a CR or PR, or had stable disease after the first treatment cycle were eligible to receive a second (consolidation) cycle of treatment over 4 weeks, following a 4-week treatment-free interval.	Cohort 3: Blinatumomab 9/28/112 μg/d Participants received blinatumomab administered CIV 9 µg/day for the first week, followed by 28 µg/day for the second week, then 112 µg/day for the remaining 6 weeks of treatment during Cycle 1. Participants who achieved CR or PR, or had stable disease after the first treatment cycle were eligible to receive a second (consolidation) cycle of treatment over 4 weeks, following a 4-week treatment-free interval.
CD3+ T-Cell Count Screening (N = 25)	0.578 1000 cells/µL Standard Deviation 0.355	—	—
CD3+ T-Cell Count Day 8 (N = 21)	0.282 1000 cells/µL Standard Deviation 0.194	—	—
CD3+ T-Cell Count Day 15 (N = 16)	0.199 1000 cells/µL Standard Deviation 0.159	—	—
CD3+ T-Cell Count Day 29 (N = 11)	0.348 1000 cells/µL Standard Deviation 0.231	—	—
CD3+ T-Cell Count Day 43 (N = 8)	0.613 1000 cells/µL Standard Deviation 0.426	—	—
CD3+ T-Cell Count End of Infusion (N = 9)	0.543 1000 cells/µL Standard Deviation 0.421	—	—
CD3+ T-Cell Count Day 1 Prior (N = 24)	0.349 1000 cells/µL Standard Deviation 0.233	—	—
CD3+ T-Cell Count End of Core Study (N = 6)	0.825 1000 cells/µL Standard Deviation 0.431	—	—
CD3+ T-Cell Count 3-Month Follow-up (N = 5)	0.773 1000 cells/µL Standard Deviation 0.443	—	—
CD3+ T-Cell Count 6-Month Follow-up (N = 6)	0.782 1000 cells/µL Standard Deviation 0.345	—	—
CD3+ T-Cell Count 9-Month Follow-up (N = 4)	0.671 1000 cells/µL Standard Deviation 0.184	—	—
CD3+ T-Cell Count 12-Month Follow-up (N = 4)	0.703 1000 cells/µL Standard Deviation 0.203	—	—
CD3+ T-Cell Count 15-Month Follow-up (N = 3)	0.594 1000 cells/µL Standard Deviation 0.227	—	—
CD3+ T-Cell Count 18-Month Follow-up (N = 3)	0.298 1000 cells/µL Standard Deviation 0.049	—	—
CD3+ T-Cell Count 21-Month Follow-up (N = 21)	0.623 1000 cells/µL Standard Deviation 0.266	—	—
CD3+ T-Cell Count 24-Month Follow-up (N = 3)	0.456 1000 cells/µL Standard Deviation 0.257	—	—

SECONDARY outcome

CD3+ T-cell counts were analyzed by flow cytometry.

Outcome measures

Outcome measures
Measure	Cohort 1: Blinatumomab 9/28/112 μg/d n=25 Participants Participants received blinatumomab administered via a continuous intravenous infusion (CIV) 9 µg/day for the first week, followed by 28 µg/day for the second week, then 112 µg/day for the remaining 6 weeks of treatment during Cycle 1. Participants who achieved a complete response (CR) or partial response (PR), or had stable disease after the first treatment cycle were eligible to receive a second (consolidation) cycle of treatment over 4 weeks, following a 4-week treatment-free interval.	Cohort 2: Blinatumomab 112 μg/d Participants received blinatumomab CIV at a constant dose of 112 µg/day for 8 weeks of treatment during Cycle 1. Participants who achieved a CR or PR, or had stable disease after the first treatment cycle were eligible to receive a second (consolidation) cycle of treatment over 4 weeks, following a 4-week treatment-free interval.	Cohort 3: Blinatumomab 9/28/112 μg/d Participants received blinatumomab administered CIV 9 µg/day for the first week, followed by 28 µg/day for the second week, then 112 µg/day for the remaining 6 weeks of treatment during Cycle 1. Participants who achieved CR or PR, or had stable disease after the first treatment cycle were eligible to receive a second (consolidation) cycle of treatment over 4 weeks, following a 4-week treatment-free interval.
CD3+ T-Cells as a Percentage of All Lymphocytes End of Core Study (N = 6)	76 percentage of lymphocytes Standard Deviation 16	—	—
CD3+ T-Cells as a Percentage of All Lymphocytes 3-Month Follow-up (N = 5)	73 percentage of lymphocytes Standard Deviation 11	—	—
CD3+ T-Cells as a Percentage of All Lymphocytes 6-Month Follow-up (N = 6)	66 percentage of lymphocytes Standard Deviation 21	—	—
CD3+ T-Cells as a Percentage of All Lymphocytes 9-Month Follow-up (N = 4)	66 percentage of lymphocytes Standard Deviation 6	—	—
CD3+ T-Cells as a Percentage of All Lymphocytes 12-Month Follow-up (N = 4)	65 percentage of lymphocytes Standard Deviation 9	—	—
CD3+ T-Cells as a Percentage of All Lymphocytes 15-Month Follow-up (N = 3)	61 percentage of lymphocytes Standard Deviation 7	—	—
CD3+ T-Cells as a Percentage of All Lymphocytes 18-Month Follow-up (N = 3)	57 percentage of lymphocytes Standard Deviation 20	—	—
CD3+ T-Cells as a Percentage of All Lymphocytes 21-Month Follow-up (N = 21)	58 percentage of lymphocytes Standard Deviation 16	—	—
CD3+ T-Cells as a Percentage of All Lymphocytes 24-Month Follow-up (N = 3)	63 percentage of lymphocytes Standard Deviation 8	—	—
CD3+ T-Cells as a Percentage of All Lymphocytes Day 15 (N = 16)	67 percentage of lymphocytes Standard Deviation 19	—	—
CD3+ T-Cells as a Percentage of All Lymphocytes Day 29 (N = 11)	73 percentage of lymphocytes Standard Deviation 15	—	—
CD3+ T-Cells as a Percentage of All Lymphocytes Day 43 (N = 8)	71 percentage of lymphocytes Standard Deviation 13	—	—
CD3+ T-Cells as a Percentage of All Lymphocytes End of Infusion (N = 9)	66 percentage of lymphocytes Standard Deviation 14	—	—
CD3+ T-Cells as a Percentage of All Lymphocytes Screening (N = 25)	72 percentage of lymphocytes Standard Deviation 14	—	—
CD3+ T-Cells as a Percentage of All Lymphocytes Day 1 Prior (N = 24)	68 percentage of lymphocytes Standard Deviation 18	—	—
CD3+ T-Cells as a Percentage of All Lymphocytes Day 8 (N = 21)	70 percentage of lymphocytes Standard Deviation 19	—	—

SECONDARY outcome

CD4+ T-cell counts were analyzed by flow cytometry.

Outcome measures

Outcome measures
Measure	Cohort 1: Blinatumomab 9/28/112 μg/d n=25 Participants Participants received blinatumomab administered via a continuous intravenous infusion (CIV) 9 µg/day for the first week, followed by 28 µg/day for the second week, then 112 µg/day for the remaining 6 weeks of treatment during Cycle 1. Participants who achieved a complete response (CR) or partial response (PR), or had stable disease after the first treatment cycle were eligible to receive a second (consolidation) cycle of treatment over 4 weeks, following a 4-week treatment-free interval.	Cohort 2: Blinatumomab 112 μg/d Participants received blinatumomab CIV at a constant dose of 112 µg/day for 8 weeks of treatment during Cycle 1. Participants who achieved a CR or PR, or had stable disease after the first treatment cycle were eligible to receive a second (consolidation) cycle of treatment over 4 weeks, following a 4-week treatment-free interval.	Cohort 3: Blinatumomab 9/28/112 μg/d Participants received blinatumomab administered CIV 9 µg/day for the first week, followed by 28 µg/day for the second week, then 112 µg/day for the remaining 6 weeks of treatment during Cycle 1. Participants who achieved CR or PR, or had stable disease after the first treatment cycle were eligible to receive a second (consolidation) cycle of treatment over 4 weeks, following a 4-week treatment-free interval.
CD4+ T-Cell Count Screening (N = 25)	0.254 1000 cells/µL Standard Deviation 0.160	—	—
CD4+ T-Cell Count Day 1 Prior (N = 24)	0.152 1000 cells/µL Standard Deviation 0.128	—	—
CD4+ T-Cell Count Day 8 (N = 21)	0.131 1000 cells/µL Standard Deviation 0.128	—	—
CD4+ T-Cell Count Day 15 (N = 16)	0.085 1000 cells/µL Standard Deviation 0.084	—	—
CD4+ T-Cell Count Day 29 (N = 11)	0.170 1000 cells/µL Standard Deviation 0.172	—	—
CD4+ T-Cell Count Day 43 (N = 8)	0.261 1000 cells/µL Standard Deviation 0.219	—	—
CD4+ T-Cell Count End of Infusion (N = 9)	0.241 1000 cells/µL Standard Deviation 0.254	—	—
CD4+ T-Cell Count End of Core Study (N = 6)	0.375 1000 cells/µL Standard Deviation 0.251	—	—
CD4+ T-Cell Count 3-Month Follow-up (N = 5)	0.371 1000 cells/µL Standard Deviation 0.216	—	—
CD4+ T-Cell Count 6-Month Follow-up (N = 6)	0.371 1000 cells/µL Standard Deviation 0.237	—	—
CD4+ T-Cell Count 9-Month Follow-up (N = 4)	0.309 1000 cells/µL Standard Deviation 0.184	—	—
CD4+ T-Cell Count 12-Month Follow-up (N = 4)	0.399 1000 cells/µL Standard Deviation 0.193	—	—
CD4+ T-Cell Count 15-Month Follow-up (N = 3)	0.326 1000 cells/µL Standard Deviation 0.220	—	—
CD4+ T-Cell Count 18-Month Follow-up (N = 3)	0.178 1000 cells/µL Standard Deviation 0.042	—	—
CD4+ T-Cell Count 21-Month Follow-up (N = 21)	0.373 1000 cells/µL Standard Deviation 0.279	—	—
CD4+ T-Cell Count 24-Month Follow-up (N = 3)	0.258 1000 cells/µL Standard Deviation 0.248	—	—

SECONDARY outcome

CD4+ T-cell counts were analyzed by flow cytometry.

Outcome measures

Outcome measures
Measure	Cohort 1: Blinatumomab 9/28/112 μg/d n=25 Participants Participants received blinatumomab administered via a continuous intravenous infusion (CIV) 9 µg/day for the first week, followed by 28 µg/day for the second week, then 112 µg/day for the remaining 6 weeks of treatment during Cycle 1. Participants who achieved a complete response (CR) or partial response (PR), or had stable disease after the first treatment cycle were eligible to receive a second (consolidation) cycle of treatment over 4 weeks, following a 4-week treatment-free interval.	Cohort 2: Blinatumomab 112 μg/d Participants received blinatumomab CIV at a constant dose of 112 µg/day for 8 weeks of treatment during Cycle 1. Participants who achieved a CR or PR, or had stable disease after the first treatment cycle were eligible to receive a second (consolidation) cycle of treatment over 4 weeks, following a 4-week treatment-free interval.	Cohort 3: Blinatumomab 9/28/112 μg/d Participants received blinatumomab administered CIV 9 µg/day for the first week, followed by 28 µg/day for the second week, then 112 µg/day for the remaining 6 weeks of treatment during Cycle 1. Participants who achieved CR or PR, or had stable disease after the first treatment cycle were eligible to receive a second (consolidation) cycle of treatment over 4 weeks, following a 4-week treatment-free interval.
CD4+ T-Cells as a Percentage of All Lymphocytes Screening (N = 25)	33 percentage of lymphocytes Standard Deviation 11	—	—
CD4+ T-Cells as a Percentage of All Lymphocytes Day 1 Prior (N = 24)	28 percentage of lymphocytes Standard Deviation 14	—	—
CD4+ T-Cells as a Percentage of All Lymphocytes Day 8 (N = 21)	32 percentage of lymphocytes Standard Deviation 17	—	—
CD4+ T-Cells as a Percentage of All Lymphocytes Day 15 (N = 16)	29 percentage of lymphocytes Standard Deviation 13	—	—
CD4+ T-Cells as a Percentage of All Lymphocytes Day 29 (N = 11)	34 percentage of lymphocytes Standard Deviation 18	—	—
CD4+ T-Cells as a Percentage of All Lymphocytes Day 43 (N = 8)	30 percentage of lymphocytes Standard Deviation 12	—	—
CD4+ T-Cells as a Percentage of All Lymphocytes End of Infusion (N = 9)	28 percentage of lymphocytes Standard Deviation 13	—	—
CD4+ T-Cells as a Percentage of All Lymphocytes End of Core Study (N = 6)	32 percentage of lymphocytes Standard Deviation 15	—	—
CD4+ T-Cells as a Percentage of All Lymphocytes 3-Month Follow-up (N = 5)	33 percentage of lymphocytes Standard Deviation 9	—	—
CD4+ T-Cells as a Percentage of All Lymphocytes 6-Month Follow-up (N = 6)	30 percentage of lymphocytes Standard Deviation 10	—	—
CD4+ T-Cells as a Percentage of All Lymphocytes 9-Month Follow-up (N = 4)	31 percentage of lymphocytes Standard Deviation 13	—	—
CD4+ T-Cells as a Percentage of All Lymphocytes 12-Month Follow-up (N = 4)	35 percentage of lymphocytes Standard Deviation 7	—	—
CD4+ T-Cells as a Percentage of All Lymphocytes 15-Month Follow-up (N = 3)	31 percentage of lymphocytes Standard Deviation 7	—	—
CD4+ T-Cells as a Percentage of All Lymphocytes 18-Month Follow-up (N = 3)	32 percentage of lymphocytes Standard Deviation 6	—	—
CD4+ T-Cells as a Percentage of All Lymphocytes 21-Month Follow-up (N = 21)	29 percentage of lymphocytes Standard Deviation 4	—	—
CD4+ T-Cells as a Percentage of All Lymphocytes 24-Month Follow-up (N = 3)	34 percentage of lymphocytes Standard Deviation 8	—	—

SECONDARY outcome

CD8+ T-cell counts were analyzed by flow cytometry.

Outcome measures

Outcome measures
Measure	Cohort 1: Blinatumomab 9/28/112 μg/d n=25 Participants Participants received blinatumomab administered via a continuous intravenous infusion (CIV) 9 µg/day for the first week, followed by 28 µg/day for the second week, then 112 µg/day for the remaining 6 weeks of treatment during Cycle 1. Participants who achieved a complete response (CR) or partial response (PR), or had stable disease after the first treatment cycle were eligible to receive a second (consolidation) cycle of treatment over 4 weeks, following a 4-week treatment-free interval.	Cohort 2: Blinatumomab 112 μg/d Participants received blinatumomab CIV at a constant dose of 112 µg/day for 8 weeks of treatment during Cycle 1. Participants who achieved a CR or PR, or had stable disease after the first treatment cycle were eligible to receive a second (consolidation) cycle of treatment over 4 weeks, following a 4-week treatment-free interval.	Cohort 3: Blinatumomab 9/28/112 μg/d Participants received blinatumomab administered CIV 9 µg/day for the first week, followed by 28 µg/day for the second week, then 112 µg/day for the remaining 6 weeks of treatment during Cycle 1. Participants who achieved CR or PR, or had stable disease after the first treatment cycle were eligible to receive a second (consolidation) cycle of treatment over 4 weeks, following a 4-week treatment-free interval.
CD8+ T-Cell Count Screening (N = 25)	0.298 1000 cells/µL Standard Deviation 0.256	—	—
CD8+ T-Cell Count Day 1 Prior (N = 24)	0.186 1000 cells/µL Standard Deviation 0.136	—	—
CD8+ T-Cell Count Day 8 (N = 21)	0.134 1000 cells/µL Standard Deviation 0.099	—	—
CD8+ T-Cell Count Day 15 (N = 16)	0.102 1000 cells/µL Standard Deviation 0.095	—	—
CD8+ T-Cell Count Day 29 (N = 11)	0.140 1000 cells/µL Standard Deviation 0.076	—	—
CD8+ T-Cell Count Day 43 (N = 8)	0.299 1000 cells/µL Standard Deviation 0.237	—	—
CD8+ T-Cell Count End of Infusion (N = 9)	0.284 1000 cells/µL Standard Deviation 0.195	—	—
CD8+ T-Cell Count End of Core Study (N = 6)	0.438 1000 cells/µL Standard Deviation 0.284	—	—
CD8+ T-Cell Count 3-Month Follow-up (N = 5)	0.381 1000 cells/µL Standard Deviation 0.254	—	—
CD8+ T-Cell Count 6-Month Follow-up (N = 6)	0.403 1000 cells/µL Standard Deviation 0.304	—	—
CD8+ T-Cell Count 9-Month Follow-up (N = 4)	0.225 1000 cells/µL Standard Deviation 0.039	—	—
CD8+ T-Cell Count 12-Month Follow-up (N = 4)	0.310 1000 cells/µL Standard Deviation 0.200	—	—
CD8+ T-Cell Count 15-Month Follow-up (N = 3)	0.214 1000 cells/µL Standard Deviation 0.023	—	—
CD8+ T-Cell Count 18-Month Follow-up (N = 3)	0.105 1000 cells/µL Standard Deviation 0.057	—	—
CD8+ T-Cell Count 21-Month Follow-up (N = 21)	0.185 1000 cells/µL Standard Deviation 0.026	—	—
CD8+ T-Cell Count 24-Month Follow-up (N = 3)	0.187 1000 cells/µL Standard Deviation 0.068	—	—

SECONDARY outcome

CD8+ T-cell counts were analyzed by flow cytometry.

Outcome measures

Outcome measures
Measure	Cohort 1: Blinatumomab 9/28/112 μg/d n=25 Participants Participants received blinatumomab administered via a continuous intravenous infusion (CIV) 9 µg/day for the first week, followed by 28 µg/day for the second week, then 112 µg/day for the remaining 6 weeks of treatment during Cycle 1. Participants who achieved a complete response (CR) or partial response (PR), or had stable disease after the first treatment cycle were eligible to receive a second (consolidation) cycle of treatment over 4 weeks, following a 4-week treatment-free interval.	Cohort 2: Blinatumomab 112 μg/d Participants received blinatumomab CIV at a constant dose of 112 µg/day for 8 weeks of treatment during Cycle 1. Participants who achieved a CR or PR, or had stable disease after the first treatment cycle were eligible to receive a second (consolidation) cycle of treatment over 4 weeks, following a 4-week treatment-free interval.	Cohort 3: Blinatumomab 9/28/112 μg/d Participants received blinatumomab administered CIV 9 µg/day for the first week, followed by 28 µg/day for the second week, then 112 µg/day for the remaining 6 weeks of treatment during Cycle 1. Participants who achieved CR or PR, or had stable disease after the first treatment cycle were eligible to receive a second (consolidation) cycle of treatment over 4 weeks, following a 4-week treatment-free interval.
CD8+ T-Cells as a Percentage of All Lymphocytes Screening (N = 25)	37 percentage of lymphocytes Standard Deviation 18	—	—
CD8+ T-Cells as a Percentage of All Lymphocytes Day 1 Prior (N = 24)	37 percentage of lymphocytes Standard Deviation 19	—	—
CD8+ T-Cells as a Percentage of All Lymphocytes Day 8 (N = 21)	35 percentage of lymphocytes Standard Deviation 19	—	—
CD8+ T-Cells as a Percentage of All Lymphocytes Day 15 (N = 16)	35 percentage of lymphocytes Standard Deviation 17	—	—
CD8+ T-Cells as a Percentage of All Lymphocytes Day 29 (N = 11)	33 percentage of lymphocytes Standard Deviation 17	—	—
CD8+ T-Cells as a Percentage of All Lymphocytes Day 43 (N = 8)	37 percentage of lymphocytes Standard Deviation 15	—	—
CD8+ T-Cells as a Percentage of All Lymphocytes End of Infusion (N = 9)	36 percentage of lymphocytes Standard Deviation 16	—	—
CD8+ T-Cells as a Percentage of All Lymphocytes End of Core Study (N = 6)	43 percentage of lymphocytes Standard Deviation 23	—	—
CD8+ T-Cells as a Percentage of All Lymphocytes 3-Month Follow-up (N = 5)	36 percentage of lymphocytes Standard Deviation 19	—	—
CD8+ T-Cells as a Percentage of All Lymphocytes 6-Month Follow-up (N = 6)	34 percentage of lymphocytes Standard Deviation 16	—	—
CD8+ T-Cells as a Percentage of All Lymphocytes 9-Month Follow-up (N = 4)	25 percentage of lymphocytes Standard Deviation 11	—	—
CD8+ T-Cells as a Percentage of All Lymphocytes 12-Month Follow-up (N = 4)	28 percentage of lymphocytes Standard Deviation 13	—	—
CD8+ T-Cells as a Percentage of All Lymphocytes 15-Month Follow-up (N = 3)	24 percentage of lymphocytes Standard Deviation 9	—	—
CD8+ T-Cells as a Percentage of All Lymphocytes 18-Month Follow-up (N = 3)	21 percentage of lymphocytes Standard Deviation 13	—	—
CD8+ T-Cells as a Percentage of All Lymphocytes 21-Month Follow-up (N = 21)	20 percentage of lymphocytes Standard Deviation 12	—	—
CD8+ T-Cells as a Percentage of All Lymphocytes 24-Month Follow-up (N = 3)	27 percentage of lymphocytes Standard Deviation 16	—	—

SECONDARY outcome

CD19+ B-cells and CD3+ T-cell counts were analyzed by flow cytometry.

Outcome measures

Outcome measures
Measure	Cohort 1: Blinatumomab 9/28/112 μg/d n=25 Participants Participants received blinatumomab administered via a continuous intravenous infusion (CIV) 9 µg/day for the first week, followed by 28 µg/day for the second week, then 112 µg/day for the remaining 6 weeks of treatment during Cycle 1. Participants who achieved a complete response (CR) or partial response (PR), or had stable disease after the first treatment cycle were eligible to receive a second (consolidation) cycle of treatment over 4 weeks, following a 4-week treatment-free interval.	Cohort 2: Blinatumomab 112 μg/d Participants received blinatumomab CIV at a constant dose of 112 µg/day for 8 weeks of treatment during Cycle 1. Participants who achieved a CR or PR, or had stable disease after the first treatment cycle were eligible to receive a second (consolidation) cycle of treatment over 4 weeks, following a 4-week treatment-free interval.	Cohort 3: Blinatumomab 9/28/112 μg/d Participants received blinatumomab administered CIV 9 µg/day for the first week, followed by 28 µg/day for the second week, then 112 µg/day for the remaining 6 weeks of treatment during Cycle 1. Participants who achieved CR or PR, or had stable disease after the first treatment cycle were eligible to receive a second (consolidation) cycle of treatment over 4 weeks, following a 4-week treatment-free interval.
CD19+ B-Cell to CD3+ T-Cell Ratio Screening (N = 25)	0.04 ratio Standard Deviation 0.15	—	—
CD19+ B-Cell to CD3+ T-Cell Ratio Day 1 Prior (N = 24)	0.07 ratio Standard Deviation 0.24	—	—
CD19+ B-Cell to CD3+ T-Cell Ratio Day 8 (N = 21)	0.00 ratio Standard Deviation 0.01	—	—
CD19+ B-Cell to CD3+ T-Cell Ratio Day 15 (N = 16)	0.00 ratio Standard Deviation 0.00	—	—
CD19+ B-Cell to CD3+ T-Cell Ratio Day 29 (N = 11)	0.00 ratio Standard Deviation 0.00	—	—
CD19+ B-Cell to CD3+ T-Cell Ratio Day 43 (N = 8)	0.00 ratio Standard Deviation 0.00	—	—
CD19+ B-Cell to CD3+ T-Cell Ratio End of Infusion (N = 9)	0.00 ratio Standard Deviation 0.01	—	—
CD19+ B-Cell to CD3+ T-Cell Ratio End of Core Study (N = 6)	0.00 ratio Standard Deviation 0.00	—	—
CD19+ B-Cell to CD3+ T-Cell Ratio 3-Month Follow-up (N = 5)	0.03 ratio Standard Deviation 0.03	—	—
CD19+ B-Cell to CD3+ T-Cell Ratio 6-Month Follow-up (N = 6)	0.04 ratio Standard Deviation 0.05	—	—
CD19+ B-Cell to CD3+ T-Cell Ratio 9-Month Follow-up (N = 4)	0.08 ratio Standard Deviation 0.08	—	—
CD19+ B-Cell to CD3+ T-Cell Ratio 12-Month Follow-up (N = 4)	0.12 ratio Standard Deviation 0.15	—	—
CD19+ B-Cell to CD3+ T-Cell Ratio 15-Month Follow-up (N = 3)	0.13 ratio Standard Deviation 0.13	—	—
CD19+ B-Cell to CD3+ T-Cell Ratio 18-Month Follow-up (N = 3)	0.25 ratio Standard Deviation 0.30	—	—
CD19+ B-Cell to CD3+ T-Cell Ratio 21-Month Follow-up (N = 21)	0.17 ratio Standard Deviation 0.20	—	—
CD19+ B-Cell to CD3+ T-Cell Ratio 24-Month Follow-up (N = 3)	0.19 ratio Standard Deviation 0.13	—	—

SECONDARY outcome

CD4+ T-cells and CD8+ T-cell counts were analyzed by flow cytometry.

Outcome measures

Outcome measures
Measure	Cohort 1: Blinatumomab 9/28/112 μg/d n=25 Participants Participants received blinatumomab administered via a continuous intravenous infusion (CIV) 9 µg/day for the first week, followed by 28 µg/day for the second week, then 112 µg/day for the remaining 6 weeks of treatment during Cycle 1. Participants who achieved a complete response (CR) or partial response (PR), or had stable disease after the first treatment cycle were eligible to receive a second (consolidation) cycle of treatment over 4 weeks, following a 4-week treatment-free interval.	Cohort 2: Blinatumomab 112 μg/d Participants received blinatumomab CIV at a constant dose of 112 µg/day for 8 weeks of treatment during Cycle 1. Participants who achieved a CR or PR, or had stable disease after the first treatment cycle were eligible to receive a second (consolidation) cycle of treatment over 4 weeks, following a 4-week treatment-free interval.	Cohort 3: Blinatumomab 9/28/112 μg/d Participants received blinatumomab administered CIV 9 µg/day for the first week, followed by 28 µg/day for the second week, then 112 µg/day for the remaining 6 weeks of treatment during Cycle 1. Participants who achieved CR or PR, or had stable disease after the first treatment cycle were eligible to receive a second (consolidation) cycle of treatment over 4 weeks, following a 4-week treatment-free interval.
CD4+ T-Cell to CD8+ T-Cell Ratio Screening (N = 25)	1.32 ratio Standard Deviation 1.19	—	—
CD4+ T-Cell to CD8+ T-Cell Ratio Day 1 Prior (N = 24)	1.16 ratio Standard Deviation 1.45	—	—
CD4+ T-Cell to CD8+ T-Cell Ratio Day 8 (N = 21)	1.20 ratio Standard Deviation 0.96	—	—
CD4+ T-Cell to CD8+ T-Cell Ratio Day 15 (N = 16)	1.03 ratio Standard Deviation 0.71	—	—
CD4+ T-Cell to CD8+ T-Cell Ratio Day 29 (N = 11)	1.43 ratio Standard Deviation 1.08	—	—
CD4+ T-Cell to CD8+ T-Cell Ratio End of Core Study (N = 6)	1.03 ratio Standard Deviation 0.80	—	—
CD4+ T-Cell to CD8+ T-Cell Ratio 3-Month Follow-up (N = 5)	1.18 ratio Standard Deviation 0.79	—	—
CD4+ T-Cell to CD8+ T-Cell Ratio 6-Month Follow-up (N = 6)	1.10 ratio Standard Deviation 0.70	—	—
CD4+ T-Cell to CD8+ T-Cell Ratio 9-Month Follow-up (N = 4)	1.53 ratio Standard Deviation 1.25	—	—
CD4+ T-Cell to CD8+ T-Cell Ratio 12-Month Follow-up (N = 4)	1.70 ratio Standard Deviation 1.47	—	—
CD4+ T-Cell to CD8+ T-Cell Ratio 15-Month Follow-up (N = 3)	1.47 ratio Standard Deviation 0.81	—	—
CD4+ T-Cell to CD8+ T-Cell Ratio 18-Month Follow-up (N = 3)	2.23 ratio Standard Deviation 1.70	—	—
CD4+ T-Cell to CD8+ T-Cell Ratio 21-Month Follow-up (N = 21)	1.85 ratio Standard Deviation 1.34	—	—
CD4+ T-Cell to CD8+ T-Cell Ratio 24-Month Follow-up (N = 3)	1.73 ratio Standard Deviation 1.21	—	—
CD4+ T-Cell to CD8+ T-Cell Ratio Day 43 (N = 8)	0.96 ratio Standard Deviation 0.53	—	—
CD4+ T-Cell to CD8+ T-Cell Ratio End of Infusion (N = 9)	1.09 ratio Standard Deviation 1.00	—	—

SECONDARY outcome

CD4+ naive T-cell counts are native T-cells characterized by the cell-surface expression of CD197 and CD45RA and were analyzed by flow cytometry.

Outcome measures

Outcome measures
Measure	Cohort 1: Blinatumomab 9/28/112 μg/d n=25 Participants Participants received blinatumomab administered via a continuous intravenous infusion (CIV) 9 µg/day for the first week, followed by 28 µg/day for the second week, then 112 µg/day for the remaining 6 weeks of treatment during Cycle 1. Participants who achieved a complete response (CR) or partial response (PR), or had stable disease after the first treatment cycle were eligible to receive a second (consolidation) cycle of treatment over 4 weeks, following a 4-week treatment-free interval.	Cohort 2: Blinatumomab 112 μg/d Participants received blinatumomab CIV at a constant dose of 112 µg/day for 8 weeks of treatment during Cycle 1. Participants who achieved a CR or PR, or had stable disease after the first treatment cycle were eligible to receive a second (consolidation) cycle of treatment over 4 weeks, following a 4-week treatment-free interval.	Cohort 3: Blinatumomab 9/28/112 μg/d Participants received blinatumomab administered CIV 9 µg/day for the first week, followed by 28 µg/day for the second week, then 112 µg/day for the remaining 6 weeks of treatment during Cycle 1. Participants who achieved CR or PR, or had stable disease after the first treatment cycle were eligible to receive a second (consolidation) cycle of treatment over 4 weeks, following a 4-week treatment-free interval.
CD4+ Naive T Cell Count Screening (N = 25)	0.028 1000 cells/µL Standard Deviation 0.056	—	—
CD4+ Naive T Cell Count Day 1 Prior (N = 24)	0.013 1000 cells/µL Standard Deviation 0.022	—	—
CD4+ Naive T Cell Count Day 8 (N = 21)	0.014 1000 cells/µL Standard Deviation 0.033	—	—
CD4+ Naive T Cell Count Day 15 (N = 16)	0.012 1000 cells/µL Standard Deviation 0.024	—	—
CD4+ Naive T Cell Count 6-Month Follow-up (N = 6)	0.023 1000 cells/µL Standard Deviation 0.044	—	—
CD4+ Naive T Cell Count 9-Month Follow-up (N = 4)	0.053 1000 cells/µL Standard Deviation 0.090	—	—
CD4+ Naive T Cell Count 12-Month Follow-up (N = 4)	0.053 1000 cells/µL Standard Deviation 0.084	—	—
CD4+ Naive T Cell Count 15-Month Follow-up (N = 3)	0.044 1000 cells/µL Standard Deviation 0.059	—	—
CD4+ Naive T Cell Count 18-Month Follow-up (N = 3)	0.035 1000 cells/µL Standard Deviation 0.041	—	—
CD4+ Naive T Cell Count 21-Month Follow-up (N = 21)	0.098 1000 cells/µL Standard Deviation 0.103	—	—
CD4+ Naive T Cell Count 24-Month Follow-up (N = 3)	0.016 1000 cells/µL Standard Deviation 0.013	—	—
CD4+ Naive T Cell Count Day 29 (N = 11)	0.032 1000 cells/µL Standard Deviation 0.071	—	—
CD4+ Naive T Cell Count Day 43 (N = 8)	0.036 1000 cells/µL Standard Deviation 0.060	—	—
CD4+ Naive T Cell Count End of Infusion (N = 9)	0.037 1000 cells/µL Standard Deviation 0.088	—	—
CD4+ Naive T Cell Count End of Core Study (N = 6)	0.050 1000 cells/µL Standard Deviation 0.083	—	—
CD4+ Naive T Cell Count 3-Month Follow-up (N = 5)	0.015 1000 cells/µL Standard Deviation 0.019	—	—

SECONDARY outcome

CD4+ naive T-cell counts are native T-cells characterized by the cell-surface expression of CD197 and CD45RA and were analyzed by flow cytometry.

Outcome measures

Outcome measures
Measure	Cohort 1: Blinatumomab 9/28/112 μg/d n=25 Participants Participants received blinatumomab administered via a continuous intravenous infusion (CIV) 9 µg/day for the first week, followed by 28 µg/day for the second week, then 112 µg/day for the remaining 6 weeks of treatment during Cycle 1. Participants who achieved a complete response (CR) or partial response (PR), or had stable disease after the first treatment cycle were eligible to receive a second (consolidation) cycle of treatment over 4 weeks, following a 4-week treatment-free interval.	Cohort 2: Blinatumomab 112 μg/d Participants received blinatumomab CIV at a constant dose of 112 µg/day for 8 weeks of treatment during Cycle 1. Participants who achieved a CR or PR, or had stable disease after the first treatment cycle were eligible to receive a second (consolidation) cycle of treatment over 4 weeks, following a 4-week treatment-free interval.	Cohort 3: Blinatumomab 9/28/112 μg/d Participants received blinatumomab administered CIV 9 µg/day for the first week, followed by 28 µg/day for the second week, then 112 µg/day for the remaining 6 weeks of treatment during Cycle 1. Participants who achieved CR or PR, or had stable disease after the first treatment cycle were eligible to receive a second (consolidation) cycle of treatment over 4 weeks, following a 4-week treatment-free interval.
CD4+ Naive T Cells as a Percentage of All CD4+ T-Cells Screening (N = 25)	8 percentage of CD4+ T-cells Standard Deviation 9	—	—
CD4+ Naive T Cells as a Percentage of All CD4+ T-Cells Day 1 Prior (N = 24)	7 percentage of CD4+ T-cells Standard Deviation 7	—	—
CD4+ Naive T Cells as a Percentage of All CD4+ T-Cells Day 8 (N = 21)	7 percentage of CD4+ T-cells Standard Deviation 7	—	—
CD4+ Naive T Cells as a Percentage of All CD4+ T-Cells Day 15 (N = 16)	10 percentage of CD4+ T-cells Standard Deviation 9	—	—
CD4+ Naive T Cells as a Percentage of All CD4+ T-Cells Day 29 (N = 11)	9 percentage of CD4+ T-cells Standard Deviation 11	—	—
CD4+ Naive T Cells as a Percentage of All CD4+ T-Cells Day 43 (N = 8)	10 percentage of CD4+ T-cells Standard Deviation 10	—	—
CD4+ Naive T Cells as a Percentage of All CD4+ T-Cells End of Infusion (N = 9)	8 percentage of CD4+ T-cells Standard Deviation 9	—	—
CD4+ Naive T Cells as a Percentage of All CD4+ T-Cells End of Core Study (N = 6)	9 percentage of CD4+ T-cells Standard Deviation 13	—	—
CD4+ Naive T Cells as a Percentage of All CD4+ T-Cells 3-Month Follow-up (N = 5)	4 percentage of CD4+ T-cells Standard Deviation 3	—	—
CD4+ Naive T Cells as a Percentage of All CD4+ T-Cells 6-Month Follow-up (N = 6)	4 percentage of CD4+ T-cells Standard Deviation 7	—	—
CD4+ Naive T Cells as a Percentage of All CD4+ T-Cells 9-Month Follow-up (N = 4)	11 percentage of CD4+ T-cells Standard Deviation 15	—	—
CD4+ Naive T Cells as a Percentage of All CD4+ T-Cells 12-Month Follow-up (N = 4)	12 percentage of CD4+ T-cells Standard Deviation 14	—	—
CD4+ Naive T Cells as a Percentage of All CD4+ T-Cells 15-Month Follow-up (N = 3)	10 percentage of CD4+ T-cells Standard Deviation 9	—	—
CD4+ Naive T Cells as a Percentage of All CD4+ T-Cells 18-Month Follow-up (N = 3)	19 percentage of CD4+ T-cells Standard Deviation 19	—	—
CD4+ Naive T Cells as a Percentage of All CD4+ T-Cells 21-Month Follow-up (N = 21)	23 percentage of CD4+ T-cells Standard Deviation 9	—	—
CD4+ Naive T Cells as a Percentage of All CD4+ T-Cells 24-Month Follow-up (N = 3)	8 percentage of CD4+ T-cells Standard Deviation 10	—	—

SECONDARY outcome

Central memory T cells are characterized by the cell-surface expression of CD197 but not CD45RA and were analyzed by flow cytometry.

Outcome measures

Outcome measures
Measure	Cohort 1: Blinatumomab 9/28/112 μg/d n=25 Participants Participants received blinatumomab administered via a continuous intravenous infusion (CIV) 9 µg/day for the first week, followed by 28 µg/day for the second week, then 112 µg/day for the remaining 6 weeks of treatment during Cycle 1. Participants who achieved a complete response (CR) or partial response (PR), or had stable disease after the first treatment cycle were eligible to receive a second (consolidation) cycle of treatment over 4 weeks, following a 4-week treatment-free interval.	Cohort 2: Blinatumomab 112 μg/d Participants received blinatumomab CIV at a constant dose of 112 µg/day for 8 weeks of treatment during Cycle 1. Participants who achieved a CR or PR, or had stable disease after the first treatment cycle were eligible to receive a second (consolidation) cycle of treatment over 4 weeks, following a 4-week treatment-free interval.	Cohort 3: Blinatumomab 9/28/112 μg/d Participants received blinatumomab administered CIV 9 µg/day for the first week, followed by 28 µg/day for the second week, then 112 µg/day for the remaining 6 weeks of treatment during Cycle 1. Participants who achieved CR or PR, or had stable disease after the first treatment cycle were eligible to receive a second (consolidation) cycle of treatment over 4 weeks, following a 4-week treatment-free interval.
CD4+ Central Memory T-Cell (TCM) Count Day 29 (N = 11)	0.032 1000 cells/µL Standard Deviation 0.065	—	—
CD4+ Central Memory T-Cell (TCM) Count Day 43 (N = 8)	0.032 1000 cells/µL Standard Deviation 0.035	—	—
CD4+ Central Memory T-Cell (TCM) Count End of Infusion (N = 9)	0.049 1000 cells/µL Standard Deviation 0.103	—	—
CD4+ Central Memory T-Cell (TCM) Count End of Core Study (N = 6)	0.062 1000 cells/µL Standard Deviation 0.075	—	—
CD4+ Central Memory T-Cell (TCM) Count 3-Month Follow-up (N = 5)	0.019 1000 cells/µL Standard Deviation 0.009	—	—
CD4+ Central Memory T-Cell (TCM) Count 6-Month Follow-up (N = 6)	0.027 1000 cells/µL Standard Deviation 0.020	—	—
CD4+ Central Memory T-Cell (TCM) Count 9-Month Follow-up (N = 4)	0.043 1000 cells/µL Standard Deviation 0.056	—	—
CD4+ Central Memory T-Cell (TCM) Count 12-Month Follow-up (N = 4)	0.065 1000 cells/µL Standard Deviation 0.073	—	—
CD4+ Central Memory T-Cell (TCM) Count 15-Month Follow-up (N = 3)	0.039 1000 cells/µL Standard Deviation 0.020	—	—
CD4+ Central Memory T-Cell (TCM) Count 18-Month Follow-up (N = 3)	0.033 1000 cells/µL Standard Deviation 0.031	—	—
CD4+ Central Memory T-Cell (TCM) Count 21-Month Follow-up (N = 21)	0.056 1000 cells/µL Standard Deviation 0.054	—	—
CD4+ Central Memory T-Cell (TCM) Count 24-Month Follow-up (N = 3)	0.021 1000 cells/µL Standard Deviation 0.010	—	—
CD4+ Central Memory T-Cell (TCM) Count Screening (N = 25)	0.048 1000 cells/µL Standard Deviation 0.053	—	—
CD4+ Central Memory T-Cell (TCM) Count Day 1 Prior (N = 24)	0.029 1000 cells/µL Standard Deviation 0.034	—	—
CD4+ Central Memory T-Cell (TCM) Count Day 8 (N = 21)	0.027 1000 cells/µL Standard Deviation 0.042	—	—
CD4+ Central Memory T-Cell (TCM) Count Day 15 (N = 16)	0.014 1000 cells/µL Standard Deviation 0.025	—	—

SECONDARY outcome

Central memory T cells are characterized by the cell-surface expression of CD197 but not CD45RA and were analyzed by flow cytometry.

Outcome measures

Outcome measures
Measure	Cohort 1: Blinatumomab 9/28/112 μg/d n=25 Participants Participants received blinatumomab administered via a continuous intravenous infusion (CIV) 9 µg/day for the first week, followed by 28 µg/day for the second week, then 112 µg/day for the remaining 6 weeks of treatment during Cycle 1. Participants who achieved a complete response (CR) or partial response (PR), or had stable disease after the first treatment cycle were eligible to receive a second (consolidation) cycle of treatment over 4 weeks, following a 4-week treatment-free interval.	Cohort 2: Blinatumomab 112 μg/d Participants received blinatumomab CIV at a constant dose of 112 µg/day for 8 weeks of treatment during Cycle 1. Participants who achieved a CR or PR, or had stable disease after the first treatment cycle were eligible to receive a second (consolidation) cycle of treatment over 4 weeks, following a 4-week treatment-free interval.	Cohort 3: Blinatumomab 9/28/112 μg/d Participants received blinatumomab administered CIV 9 µg/day for the first week, followed by 28 µg/day for the second week, then 112 µg/day for the remaining 6 weeks of treatment during Cycle 1. Participants who achieved CR or PR, or had stable disease after the first treatment cycle were eligible to receive a second (consolidation) cycle of treatment over 4 weeks, following a 4-week treatment-free interval.
CD4+ TCM Cells as a Percentage of All CD4+ T-Cells Day 1 Prior (N = 24)	20 percentage of CD4+ T-cells Standard Deviation 15	—	—
CD4+ TCM Cells as a Percentage of All CD4+ T-Cells Day 8 (N = 21)	19 percentage of CD4+ T-cells Standard Deviation 15	—	—
CD4+ TCM Cells as a Percentage of All CD4+ T-Cells Day 15 (N = 16)	14 percentage of CD4+ T-cells Standard Deviation 12	—	—
CD4+ TCM Cells as a Percentage of All CD4+ T-Cells Day 29 (N = 11)	13 percentage of CD4+ T-cells Standard Deviation 10	—	—
CD4+ TCM Cells as a Percentage of All CD4+ T-Cells Day 43 (N = 8)	13 percentage of CD4+ T-cells Standard Deviation 9	—	—
CD4+ TCM Cells as a Percentage of All CD4+ T-Cells End of Infusion (N = 9)	15 percentage of CD4+ T-cells Standard Deviation 11	—	—
CD4+ TCM Cells as a Percentage of All CD4+ T-Cells End of Core Study (N = 6)	14 percentage of CD4+ T-cells Standard Deviation 11	—	—
CD4+ TCM Cells as a Percentage of All CD4+ T-Cells 6-Month Follow-up (N = 6)	9 percentage of CD4+ T-cells Standard Deviation 4	—	—
CD4+ TCM Cells as a Percentage of All CD4+ T-Cells 9-Month Follow-up (N = 4)	11 percentage of CD4+ T-cells Standard Deviation 9	—	—
CD4+ TCM Cells as a Percentage of All CD4+ T-Cells Screening (N = 25)	18 percentage of CD4+ T-cells Standard Deviation 12	—	—
CD4+ TCM Cells as a Percentage of All CD4+ T-Cells 3-Month Follow-up (N = 5)	6 percentage of CD4+ T-cells Standard Deviation 3	—	—
CD4+ TCM Cells as a Percentage of All CD4+ T-Cells 12-Month Follow-up (N = 4)	18 percentage of CD4+ T-cells Standard Deviation 16	—	—
CD4+ TCM Cells as a Percentage of All CD4+ T-Cells 15-Month Follow-up (N = 3)	13 percentage of CD4+ T-cells Standard Deviation 6	—	—
CD4+ TCM Cells as a Percentage of All CD4+ T-Cells 18-Month Follow-up (N = 3)	18 percentage of CD4+ T-cells Standard Deviation 14	—	—
CD4+ TCM Cells as a Percentage of All CD4+ T-Cells 21-Month Follow-up (N = 21)	14 percentage of CD4+ T-cells Standard Deviation 4	—	—
CD4+ TCM Cells as a Percentage of All CD4+ T-Cells 24-Month Follow-up (N = 3)	12 percentage of CD4+ T-cells Standard Deviation 11	—	—

SECONDARY outcome

Effector memory T cells are characterized by the lack of expression of CD197 and CD45RA and were analyzed by flow cytometry.

Outcome measures

Outcome measures
Measure	Cohort 1: Blinatumomab 9/28/112 μg/d n=25 Participants Participants received blinatumomab administered via a continuous intravenous infusion (CIV) 9 µg/day for the first week, followed by 28 µg/day for the second week, then 112 µg/day for the remaining 6 weeks of treatment during Cycle 1. Participants who achieved a complete response (CR) or partial response (PR), or had stable disease after the first treatment cycle were eligible to receive a second (consolidation) cycle of treatment over 4 weeks, following a 4-week treatment-free interval.	Cohort 2: Blinatumomab 112 μg/d Participants received blinatumomab CIV at a constant dose of 112 µg/day for 8 weeks of treatment during Cycle 1. Participants who achieved a CR or PR, or had stable disease after the first treatment cycle were eligible to receive a second (consolidation) cycle of treatment over 4 weeks, following a 4-week treatment-free interval.	Cohort 3: Blinatumomab 9/28/112 μg/d Participants received blinatumomab administered CIV 9 µg/day for the first week, followed by 28 µg/day for the second week, then 112 µg/day for the remaining 6 weeks of treatment during Cycle 1. Participants who achieved CR or PR, or had stable disease after the first treatment cycle were eligible to receive a second (consolidation) cycle of treatment over 4 weeks, following a 4-week treatment-free interval.
CD4+ Effector Memory T-Cell (TEM) Count Day 15 (N = 16)	0.051 1000 cells/µL Standard Deviation 0.044	—	—
CD4+ Effector Memory T-Cell (TEM) Count Day 29 (N = 11)	0.097 1000 cells/µL Standard Deviation 0.059	—	—
CD4+ Effector Memory T-Cell (TEM) Count Day 43 (N = 8)	0.169 1000 cells/µL Standard Deviation 0.117	—	—
CD4+ Effector Memory T-Cell (TEM) Count End of Infusion (N = 9)	0.140 1000 cells/µL Standard Deviation 0.091	—	—
CD4+ Effector Memory T-Cell (TEM) Count End of Core Study (N = 6)	0.220 1000 cells/µL Standard Deviation 0.142	—	—
CD4+ Effector Memory T-Cell (TEM) Count Screening (N = 25)	0.161 1000 cells/µL Standard Deviation 0.089	—	—
CD4+ Effector Memory T-Cell (TEM) Count Day 1 Prior (N = 24)	0.099 1000 cells/µL Standard Deviation 0.096	—	—
CD4+ Effector Memory T-Cell (TEM) Count Day 8 (N = 21)	0.083 1000 cells/µL Standard Deviation 0.076	—	—
CD4+ Effector Memory T-Cell (TEM) Count 3-Month Follow-up (N = 5)	0.279 1000 cells/µL Standard Deviation 0.153	—	—
CD4+ Effector Memory T-Cell (TEM) Count 6-Month Follow-up (N = 6)	0.267 1000 cells/µL Standard Deviation 0.158	—	—
CD4+ Effector Memory T-Cell (TEM) Count 9-Month Follow-up (N = 4)	0.191 1000 cells/µL Standard Deviation 0.037	—	—
CD4+ Effector Memory T-Cell (TEM) Count 12-Month Follow-up (N = 4)	0.226 1000 cells/µL Standard Deviation 0.100	—	—
CD4+ Effector Memory T-Cell (TEM) Count 15-Month Follow-up (N = 3)	0.199 1000 cells/µL Standard Deviation 0.087	—	—
CD4+ Effector Memory T-Cell (TEM) Count 18-Month Follow-up (N = 3)	0.106 1000 cells/µL Standard Deviation 0.066	—	—
CD4+ Effector Memory T-Cell (TEM) Count 21-Month Follow-up (N = 21)	0.181 1000 cells/µL Standard Deviation 0.107	—	—
CD4+ Effector Memory T-Cell (TEM) Count 24-Month Follow-up (N = 3)	0.175 1000 cells/µL Standard Deviation 0.133	—	—

SECONDARY outcome

Effector memory T cells are characterized by the lack of expression of CD197 and CD45RA and were analyzed by flow cytometry.

Outcome measures

Outcome measures
Measure	Cohort 1: Blinatumomab 9/28/112 μg/d n=25 Participants Participants received blinatumomab administered via a continuous intravenous infusion (CIV) 9 µg/day for the first week, followed by 28 µg/day for the second week, then 112 µg/day for the remaining 6 weeks of treatment during Cycle 1. Participants who achieved a complete response (CR) or partial response (PR), or had stable disease after the first treatment cycle were eligible to receive a second (consolidation) cycle of treatment over 4 weeks, following a 4-week treatment-free interval.	Cohort 2: Blinatumomab 112 μg/d Participants received blinatumomab CIV at a constant dose of 112 µg/day for 8 weeks of treatment during Cycle 1. Participants who achieved a CR or PR, or had stable disease after the first treatment cycle were eligible to receive a second (consolidation) cycle of treatment over 4 weeks, following a 4-week treatment-free interval.	Cohort 3: Blinatumomab 9/28/112 μg/d Participants received blinatumomab administered CIV 9 µg/day for the first week, followed by 28 µg/day for the second week, then 112 µg/day for the remaining 6 weeks of treatment during Cycle 1. Participants who achieved CR or PR, or had stable disease after the first treatment cycle were eligible to receive a second (consolidation) cycle of treatment over 4 weeks, following a 4-week treatment-free interval.
CD4+ TEM Cells as a Percentage of All CD4+ T-Cells 9-Month Follow-up (N = 4)	42 percentage of CD4+ T-cells Standard Deviation 18	—	—
CD4+ TEM Cells as a Percentage of All CD4+ T-Cells 12-Month Follow-up (N = 4)	40 percentage of CD4+ T-cells Standard Deviation 15	—	—
CD4+ TEM Cells as a Percentage of All CD4+ T-Cells 15-Month Follow-up (N = 3)	46 percentage of CD4+ T-cells Standard Deviation 17	—	—
CD4+ TEM Cells as a Percentage of All CD4+ T-Cells 18-Month Follow-up (N = 3)	43 percentage of CD4+ T-cells Standard Deviation 12	—	—
CD4+ TEM Cells as a Percentage of All CD4+ T-Cells 21-Month Follow-up (N = 21)	45 percentage of CD4+ T-cells Standard Deviation 3	—	—
CD4+ TEM Cells as a Percentage of All CD4+ T-Cells 24-Month Follow-up (N = 3)	51 percentage of CD4+ T-cells Standard Deviation 22	—	—
CD4+ TEM Cells as a Percentage of All CD4+ T-Cells Screening (N = 25)	41 percentage of CD4+ T-cells Standard Deviation 19	—	—
CD4+ TEM Cells as a Percentage of All CD4+ T-Cells Day 1 Prior (N = 24)	39 percentage of CD4+ T-cells Standard Deviation 19	—	—
CD4+ TEM Cells as a Percentage of All CD4+ T-Cells Day 8 (N = 21)	36 percentage of CD4+ T-cells Standard Deviation 19	—	—
CD4+ TEM Cells as a Percentage of All CD4+ T-Cells Day 15 (N = 16)	46 percentage of CD4+ T-cells Standard Deviation 17	—	—
CD4+ TEM Cells as a Percentage of All CD4+ T-Cells Day 29 (N = 11)	34 percentage of CD4+ T-cells Standard Deviation 20	—	—
CD4+ TEM Cells as a Percentage of All CD4+ T-Cells Day 43 (N = 8)	39 percentage of CD4+ T-cells Standard Deviation 26	—	—
CD4+ TEM Cells as a Percentage of All CD4+ T-Cells End of Infusion (N = 9)	41 percentage of CD4+ T-cells Standard Deviation 24	—	—
CD4+ TEM Cells as a Percentage of All CD4+ T-Cells End of Core Study (N = 6)	41 percentage of CD4+ T-cells Standard Deviation 24	—	—
CD4+ TEM Cells as a Percentage of All CD4+ T-Cells 3-Month Follow-up (N = 5)	46 percentage of CD4+ T-cells Standard Deviation 26	—	—
CD4+ TEM Cells as a Percentage of All CD4+ T-Cells 6-Month Follow-up (N = 6)	41 percentage of CD4+ T-cells Standard Deviation 21	—	—

SECONDARY outcome

CD8+ naive T-cell counts are native T-cells characterized by the cell-surface expression of CD197 and CD45RA and were analyzed by flow cytometry.

Outcome measures

Outcome measures
Measure	Cohort 1: Blinatumomab 9/28/112 μg/d n=25 Participants Participants received blinatumomab administered via a continuous intravenous infusion (CIV) 9 µg/day for the first week, followed by 28 µg/day for the second week, then 112 µg/day for the remaining 6 weeks of treatment during Cycle 1. Participants who achieved a complete response (CR) or partial response (PR), or had stable disease after the first treatment cycle were eligible to receive a second (consolidation) cycle of treatment over 4 weeks, following a 4-week treatment-free interval.	Cohort 2: Blinatumomab 112 μg/d Participants received blinatumomab CIV at a constant dose of 112 µg/day for 8 weeks of treatment during Cycle 1. Participants who achieved a CR or PR, or had stable disease after the first treatment cycle were eligible to receive a second (consolidation) cycle of treatment over 4 weeks, following a 4-week treatment-free interval.	Cohort 3: Blinatumomab 9/28/112 μg/d Participants received blinatumomab administered CIV 9 µg/day for the first week, followed by 28 µg/day for the second week, then 112 µg/day for the remaining 6 weeks of treatment during Cycle 1. Participants who achieved CR or PR, or had stable disease after the first treatment cycle were eligible to receive a second (consolidation) cycle of treatment over 4 weeks, following a 4-week treatment-free interval.
CD8+ Naive T-Cell Count Screening (N = 25)	0.029 1000 cells/µL Standard Deviation 0.043	—	—
CD8+ Naive T-Cell Count Day 1 Prior (N = 24)	0.024 1000 cells/µL Standard Deviation 0.050	—	—
CD8+ Naive T-Cell Count Day 8 (N = 21)	0.010 1000 cells/µL Standard Deviation 0.012	—	—
CD8+ Naive T-Cell Count Day 15 (N = 16)	0.006 1000 cells/µL Standard Deviation 0.005	—	—
CD8+ Naive T-Cell Count Day 29 (N = 11)	0.012 1000 cells/µL Standard Deviation 0.014	—	—
CD8+ Naive T-Cell Count 6-Month Follow-up (N = 6)	0.020 1000 cells/µL Standard Deviation 0.022	—	—
CD8+ Naive T-Cell Count 9-Month Follow-up (N = 4)	0.011 1000 cells/µL Standard Deviation 0.012	—	—
CD8+ Naive T-Cell Count 12-Month Follow-up (N = 4)	0.011 1000 cells/µL Standard Deviation 0.009	—	—
CD8+ Naive T-Cell Count 15-Month Follow-up (N = 3)	0.014 1000 cells/µL Standard Deviation 0.011	—	—
CD8+ Naive T-Cell Count 18-Month Follow-up (N = 3)	0.007 1000 cells/µL Standard Deviation 0.008	—	—
CD8+ Naive T-Cell Count 21-Month Follow-up (N = 21)	0.015 1000 cells/µL Standard Deviation 0.006	—	—
CD8+ Naive T-Cell Count 24-Month Follow-up (N = 3)	0.010 1000 cells/µL Standard Deviation 0.009	—	—
CD8+ Naive T-Cell Count Day 43 (N = 8)	0.019 1000 cells/µL Standard Deviation 0.036	—	—
CD8+ Naive T-Cell Count End of Infusion (N = 9)	0.011 1000 cells/µL Standard Deviation 0.015	—	—
CD8+ Naive T-Cell Count End of Core Study (N = 6)	0.023 1000 cells/µL Standard Deviation 0.018	—	—
CD8+ Naive T-Cell Count 3-Month Follow-up (N = 5)	0.011 1000 cells/µL Standard Deviation 0.007	—	—

SECONDARY outcome

CD8+ naive T-cell counts are native T-cells characterized by the cell-surface expression of CD197 and CD45RA and were analyzed by flow cytometry.

Outcome measures

Outcome measures
Measure	Cohort 1: Blinatumomab 9/28/112 μg/d n=25 Participants Participants received blinatumomab administered via a continuous intravenous infusion (CIV) 9 µg/day for the first week, followed by 28 µg/day for the second week, then 112 µg/day for the remaining 6 weeks of treatment during Cycle 1. Participants who achieved a complete response (CR) or partial response (PR), or had stable disease after the first treatment cycle were eligible to receive a second (consolidation) cycle of treatment over 4 weeks, following a 4-week treatment-free interval.	Cohort 2: Blinatumomab 112 μg/d Participants received blinatumomab CIV at a constant dose of 112 µg/day for 8 weeks of treatment during Cycle 1. Participants who achieved a CR or PR, or had stable disease after the first treatment cycle were eligible to receive a second (consolidation) cycle of treatment over 4 weeks, following a 4-week treatment-free interval.	Cohort 3: Blinatumomab 9/28/112 μg/d Participants received blinatumomab administered CIV 9 µg/day for the first week, followed by 28 µg/day for the second week, then 112 µg/day for the remaining 6 weeks of treatment during Cycle 1. Participants who achieved CR or PR, or had stable disease after the first treatment cycle were eligible to receive a second (consolidation) cycle of treatment over 4 weeks, following a 4-week treatment-free interval.
CD8+ Naive T-Cells as a Percentage of All CD8+ T-Cells Screening (N = 25)	10 percentage of CD8+ T-cells Standard Deviation 10	—	—
CD8+ Naive T-Cells as a Percentage of All CD8+ T-Cells Day 1 Prior (N = 24)	12 percentage of CD8+ T-cells Standard Deviation 13	—	—
CD8+ Naive T-Cells as a Percentage of All CD8+ T-Cells Day 8 (N = 21)	9 percentage of CD8+ T-cells Standard Deviation 8	—	—
CD8+ Naive T-Cells as a Percentage of All CD8+ T-Cells Day 15 (N = 16)	8 percentage of CD8+ T-cells Standard Deviation 7	—	—
CD8+ Naive T-Cells as a Percentage of All CD8+ T-Cells Day 29 (N = 11)	8 percentage of CD8+ T-cells Standard Deviation 7	—	—
CD8+ Naive T-Cells as a Percentage of All CD8+ T-Cells Day 43 (N = 8)	6 percentage of CD8+ T-cells Standard Deviation 7	—	—
CD8+ Naive T-Cells as a Percentage of All CD8+ T-Cells End of Infusion (N = 9)	3 percentage of CD8+ T-cells Standard Deviation 3	—	—
CD8+ Naive T-Cells as a Percentage of All CD8+ T-Cells End of Core Study (N = 6)	6 percentage of CD8+ T-cells Standard Deviation 6	—	—
CD8+ Naive T-Cells as a Percentage of All CD8+ T-Cells 3-Month Follow-up (N = 5)	4 percentage of CD8+ T-cells Standard Deviation 4	—	—
CD8+ Naive T-Cells as a Percentage of All CD8+ T-Cells 6-Month Follow-up (N = 6)	5 percentage of CD8+ T-cells Standard Deviation 5	—	—
CD8+ Naive T-Cells as a Percentage of All CD8+ T-Cells 9-Month Follow-up (N = 4)	6 percentage of CD8+ T-cells Standard Deviation 7	—	—
CD8+ Naive T-Cells as a Percentage of All CD8+ T-Cells 12-Month Follow-up (N = 4)	6 percentage of CD8+ T-cells Standard Deviation 6	—	—
CD8+ Naive T-Cells as a Percentage of All CD8+ T-Cells 15-Month Follow-up (N = 3)	6 percentage of CD8+ T-cells Standard Deviation 5	—	—
CD8+ Naive T-Cells as a Percentage of All CD8+ T-Cells 18-Month Follow-up (N = 3)	10 percentage of CD8+ T-cells Standard Deviation 8	—	—
CD8+ Naive T-Cells as a Percentage of All CD8+ T-Cells 21-Month Follow-up (N = 21)	8 percentage of CD8+ T-cells Standard Deviation 4	—	—
CD8+ Naive T-Cells as a Percentage of All CD8+ T-Cells 24-Month Follow-up (N = 3)	10 percentage of CD8+ T-cells Standard Deviation 12	—	—

SECONDARY outcome

Central memory T cells are characterized by the cell-surface expression of CD197 but not CD45RA and were analyzed by flow cytometry.

Outcome measures

Outcome measures
Measure	Cohort 1: Blinatumomab 9/28/112 μg/d n=25 Participants Participants received blinatumomab administered via a continuous intravenous infusion (CIV) 9 µg/day for the first week, followed by 28 µg/day for the second week, then 112 µg/day for the remaining 6 weeks of treatment during Cycle 1. Participants who achieved a complete response (CR) or partial response (PR), or had stable disease after the first treatment cycle were eligible to receive a second (consolidation) cycle of treatment over 4 weeks, following a 4-week treatment-free interval.	Cohort 2: Blinatumomab 112 μg/d Participants received blinatumomab CIV at a constant dose of 112 µg/day for 8 weeks of treatment during Cycle 1. Participants who achieved a CR or PR, or had stable disease after the first treatment cycle were eligible to receive a second (consolidation) cycle of treatment over 4 weeks, following a 4-week treatment-free interval.	Cohort 3: Blinatumomab 9/28/112 μg/d Participants received blinatumomab administered CIV 9 µg/day for the first week, followed by 28 µg/day for the second week, then 112 µg/day for the remaining 6 weeks of treatment during Cycle 1. Participants who achieved CR or PR, or had stable disease after the first treatment cycle were eligible to receive a second (consolidation) cycle of treatment over 4 weeks, following a 4-week treatment-free interval.
CD8+ TCM Cell Counts Day 8 (N = 21)	0.010 100 cells/µL Standard Deviation 0.013	—	—
CD8+ TCM Cell Counts Day 15 (N = 16)	0.004 100 cells/µL Standard Deviation 0.005	—	—
CD8+ TCM Cell Counts Day 29 (N = 11)	0.007 100 cells/µL Standard Deviation 0.007	—	—
CD8+ TCM Cell Counts Day 43 (N = 8)	0.012 100 cells/µL Standard Deviation 0.015	—	—
CD8+ TCM Cell Counts End of Infusion (N = 9)	0.009 100 cells/µL Standard Deviation 0.009	—	—
CD8+ TCM Cell Counts End of Core Study (N = 6)	0.016 100 cells/µL Standard Deviation 0.023	—	—
CD8+ TCM Cell Counts 3-Month Follow-up (N = 5)	0.008 100 cells/µL Standard Deviation 0.003	—	—
CD8+ TCM Cell Counts 6-Month Follow-up (N = 6)	0.016 100 cells/µL Standard Deviation 0.014	—	—
CD8+ TCM Cell Counts 9-Month Follow-up (N = 4)	0.006 100 cells/µL Standard Deviation 0.004	—	—
CD8+ TCM Cell Counts 12-Month Follow-up (N = 4)	0.010 100 cells/µL Standard Deviation 0.010	—	—
CD8+ TCM Cell Counts 15-Month Follow-up (N = 3)	0.004 100 cells/µL Standard Deviation 0.002	—	—
CD8+ TCM Cell Counts Screening (N = 25)	0.020 100 cells/µL Standard Deviation 0.027	—	—
CD8+ TCM Cell Counts Day 1 Prior (N = 24)	0.014 100 cells/µL Standard Deviation 0.021	—	—
CD8+ TCM Cell Counts 18-Month Follow-up (N = 3)	0.002 100 cells/µL Standard Deviation 0.001	—	—
CD8+ TCM Cell Counts 21-Month Follow-up (N = 21)	0.002 100 cells/µL Standard Deviation 0.001	—	—
CD8+ TCM Cell Counts 24-Month Follow-up (N = 3)	0.006 100 cells/µL Standard Deviation 0.004	—	—

SECONDARY outcome

Central memory T cells are characterized by the cell-surface expression of CD197 but not CD45RA and were analyzed by flow cytometry.

Outcome measures

Outcome measures
Measure	Cohort 1: Blinatumomab 9/28/112 μg/d n=25 Participants Participants received blinatumomab administered via a continuous intravenous infusion (CIV) 9 µg/day for the first week, followed by 28 µg/day for the second week, then 112 µg/day for the remaining 6 weeks of treatment during Cycle 1. Participants who achieved a complete response (CR) or partial response (PR), or had stable disease after the first treatment cycle were eligible to receive a second (consolidation) cycle of treatment over 4 weeks, following a 4-week treatment-free interval.	Cohort 2: Blinatumomab 112 μg/d Participants received blinatumomab CIV at a constant dose of 112 µg/day for 8 weeks of treatment during Cycle 1. Participants who achieved a CR or PR, or had stable disease after the first treatment cycle were eligible to receive a second (consolidation) cycle of treatment over 4 weeks, following a 4-week treatment-free interval.	Cohort 3: Blinatumomab 9/28/112 μg/d Participants received blinatumomab administered CIV 9 µg/day for the first week, followed by 28 µg/day for the second week, then 112 µg/day for the remaining 6 weeks of treatment during Cycle 1. Participants who achieved CR or PR, or had stable disease after the first treatment cycle were eligible to receive a second (consolidation) cycle of treatment over 4 weeks, following a 4-week treatment-free interval.
CD8+ TCM Cells as a Percentage of All CD8+ T-Cells Day 1 Prior (N = 24)	8 percentage of CD8+ T-cells Standard Deviation 11	—	—
CD8+ TCM Cells as a Percentage of All CD8+ T-Cells Day 8 (N = 21)	10 percentage of CD8+ T-cells Standard Deviation 13	—	—
CD8+ TCM Cells as a Percentage of All CD8+ T-Cells Day 15 (N = 16)	4 percentage of CD8+ T-cells Standard Deviation 5	—	—
CD8+ TCM Cells as a Percentage of All CD8+ T-Cells Day 29 (N = 11)	7 percentage of CD8+ T-cells Standard Deviation 10	—	—
CD8+ TCM Cells as a Percentage of All CD8+ T-Cells Day 43 (N = 8)	9 percentage of CD8+ T-cells Standard Deviation 18	—	—
CD8+ TCM Cells as a Percentage of All CD8+ T-Cells End of Infusion (N = 9)	5 percentage of CD8+ T-cells Standard Deviation 6	—	—
CD8+ TCM Cells as a Percentage of All CD8+ T-Cells End of Core Study (N = 6)	5 percentage of CD8+ T-cells Standard Deviation 8	—	—
CD8+ TCM Cells as a Percentage of All CD8+ T-Cells 3-Month Follow-up (N = 5)	3 percentage of CD8+ T-cells Standard Deviation 2	—	—
CD8+ TCM Cells as a Percentage of All CD8+ T-Cells 6-Month Follow-up (N = 6)	4 percentage of CD8+ T-cells Standard Deviation 3	—	—
CD8+ TCM Cells as a Percentage of All CD8+ T-Cells 9-Month Follow-up (N = 4)	3 percentage of CD8+ T-cells Standard Deviation 2	—	—
CD8+ TCM Cells as a Percentage of All CD8+ T-Cells 12-Month Follow-up (N = 4)	3 percentage of CD8+ T-cells Standard Deviation 3	—	—
CD8+ TCM Cells as a Percentage of All CD8+ T-Cells 15-Month Follow-up (N = 3)	2 percentage of CD8+ T-cells Standard Deviation 1	—	—
CD8+ TCM Cells as a Percentage of All CD8+ T-Cells 18-Month Follow-up (N = 3)	2 percentage of CD8+ T-cells Standard Deviation 1	—	—
CD8+ TCM Cells as a Percentage of All CD8+ T-Cells 21-Month Follow-up (N = 21)	1 percentage of CD8+ T-cells Standard Deviation 0	—	—
CD8+ TCM Cells as a Percentage of All CD8+ T-Cells 24-Month Follow-up (N = 3)	6 percentage of CD8+ T-cells Standard Deviation 8	—	—
CD8+ TCM Cells as a Percentage of All CD8+ T-Cells Screening (N = 25)	7 percentage of CD8+ T-cells Standard Deviation 7	—	—

SECONDARY outcome

Effector memory T cells are characterized by the lack of expression of CD197 and CD45RA and were analyzed by flow cytometry.

Outcome measures

Outcome measures
Measure	Cohort 1: Blinatumomab 9/28/112 μg/d n=25 Participants Participants received blinatumomab administered via a continuous intravenous infusion (CIV) 9 µg/day for the first week, followed by 28 µg/day for the second week, then 112 µg/day for the remaining 6 weeks of treatment during Cycle 1. Participants who achieved a complete response (CR) or partial response (PR), or had stable disease after the first treatment cycle were eligible to receive a second (consolidation) cycle of treatment over 4 weeks, following a 4-week treatment-free interval.	Cohort 2: Blinatumomab 112 μg/d Participants received blinatumomab CIV at a constant dose of 112 µg/day for 8 weeks of treatment during Cycle 1. Participants who achieved a CR or PR, or had stable disease after the first treatment cycle were eligible to receive a second (consolidation) cycle of treatment over 4 weeks, following a 4-week treatment-free interval.	Cohort 3: Blinatumomab 9/28/112 μg/d Participants received blinatumomab administered CIV 9 µg/day for the first week, followed by 28 µg/day for the second week, then 112 µg/day for the remaining 6 weeks of treatment during Cycle 1. Participants who achieved CR or PR, or had stable disease after the first treatment cycle were eligible to receive a second (consolidation) cycle of treatment over 4 weeks, following a 4-week treatment-free interval.
CD8+ Effector Memory T-Cell (TEM) Count Screening (N = 25)	0.127 1000 cells/µL Standard Deviation 0.162	—	—
CD8+ Effector Memory T-Cell (TEM) Count Day 1 Prior (N = 24)	0.075 1000 cells/µL Standard Deviation 0.066	—	—
CD8+ Effector Memory T-Cell (TEM) Count Day 8 (N = 21)	0.065 1000 cells/µL Standard Deviation 0.058	—	—
CD8+ Effector Memory T-Cell (TEM) Count Day 15 (N = 16)	0.045 1000 cells/µL Standard Deviation 0.053	—	—
CD8+ Effector Memory T-Cell (TEM) Count Day 29 (N = 11)	0.067 1000 cells/µL Standard Deviation 0.039	—	—
CD8+ Effector Memory T-Cell (TEM) Count Day 43 (N = 8)	0.135 1000 cells/µL Standard Deviation 0.108	—	—
CD8+ Effector Memory T-Cell (TEM) Count End of Infusion (N = 9)	0.128 1000 cells/µL Standard Deviation 0.077	—	—
CD8+ Effector Memory T-Cell (TEM) Count End of Core Study (N = 6)	0.180 1000 cells/µL Standard Deviation 0.089	—	—
CD8+ Effector Memory T-Cell (TEM) Count 3-Month Follow-up (N = 5)	0.146 1000 cells/µL Standard Deviation 0.071	—	—
CD8+ Effector Memory T-Cell (TEM) Count 6-Month Follow-up (N = 6)	0.179 1000 cells/µL Standard Deviation 0.158	—	—
CD8+ Effector Memory T-Cell (TEM) Count 9-Month Follow-up (N = 4)	0.116 1000 cells/µL Standard Deviation 0.061	—	—
CD8+ Effector Memory T-Cell (TEM) Count 12-Month Follow-up (N = 4)	0.174 1000 cells/µL Standard Deviation 0.162	—	—
CD8+ Effector Memory T-Cell (TEM) Count 15-Month Follow-up (N = 3)	0.095 1000 cells/µL Standard Deviation 0.025	—	—
CD8+ Effector Memory T-Cell (TEM) Count 21-Month Follow-up (N = 21)	0.085 1000 cells/µL Standard Deviation 0.013	—	—
CD8+ Effector Memory T-Cell (TEM) Count 24-Month Follow-up (N = 3)	0.054 1000 cells/µL Standard Deviation 0.027	—	—
CD8+ Effector Memory T-Cell (TEM) Count 18-Month Follow-up (N = 3)	0.049 1000 cells/µL Standard Deviation 0.027	—	—

SECONDARY outcome

Effector memory T cells are characterized by the lack of expression of CD197 and CD45RA and were analyzed by flow cytometry.

Outcome measures

Outcome measures
Measure	Cohort 1: Blinatumomab 9/28/112 μg/d n=25 Participants Participants received blinatumomab administered via a continuous intravenous infusion (CIV) 9 µg/day for the first week, followed by 28 µg/day for the second week, then 112 µg/day for the remaining 6 weeks of treatment during Cycle 1. Participants who achieved a complete response (CR) or partial response (PR), or had stable disease after the first treatment cycle were eligible to receive a second (consolidation) cycle of treatment over 4 weeks, following a 4-week treatment-free interval.	Cohort 2: Blinatumomab 112 μg/d Participants received blinatumomab CIV at a constant dose of 112 µg/day for 8 weeks of treatment during Cycle 1. Participants who achieved a CR or PR, or had stable disease after the first treatment cycle were eligible to receive a second (consolidation) cycle of treatment over 4 weeks, following a 4-week treatment-free interval.	Cohort 3: Blinatumomab 9/28/112 μg/d Participants received blinatumomab administered CIV 9 µg/day for the first week, followed by 28 µg/day for the second week, then 112 µg/day for the remaining 6 weeks of treatment during Cycle 1. Participants who achieved CR or PR, or had stable disease after the first treatment cycle were eligible to receive a second (consolidation) cycle of treatment over 4 weeks, following a 4-week treatment-free interval.
CD8+ TEM Cells as a Percentage of All CD8+ T-Cells Screening (N = 25)	42 percentage of CD8+ T-cells Standard Deviation 19	—	—
CD8+ TEM Cells as a Percentage of All CD8+ T-Cells Day 1 Prior (N = 24)	42 percentage of CD8+ T-cells Standard Deviation 17	—	—
CD8+ TEM Cells as a Percentage of All CD8+ T-Cells Day 8 (N = 21)	46 percentage of CD8+ T-cells Standard Deviation 18	—	—
CD8+ TEM Cells as a Percentage of All CD8+ T-Cells Day 15 (N = 16)	43 percentage of CD8+ T-cells Standard Deviation 13	—	—
CD8+ TEM Cells as a Percentage of All CD8+ T-Cells Day 29 (N = 11)	51 percentage of CD8+ T-cells Standard Deviation 19	—	—
CD8+ TEM Cells as a Percentage of All CD8+ T-Cells Day 43 (N = 8)	46 percentage of CD8+ T-cells Standard Deviation 23	—	—
CD8+ TEM Cells as a Percentage of All CD8+ T-Cells End of Infusion (N = 9)	51 percentage of CD8+ T-cells Standard Deviation 21	—	—
CD8+ TEM Cells as a Percentage of All CD8+ T-Cells End of Core Study (N = 6)	49 percentage of CD8+ T-cells Standard Deviation 22	—	—
CD8+ TEM Cells as a Percentage of All CD8+ T-Cells 3-Month Follow-up (N = 5)	47 percentage of CD8+ T-cells Standard Deviation 23	—	—
CD8+ TEM Cells as a Percentage of All CD8+ T-Cells 6-Month Follow-up (N = 6)	50 percentage of CD8+ T-cells Standard Deviation 24	—	—
CD8+ TEM Cells as a Percentage of All CD8+ T-Cells 9-Month Follow-up (N = 4)	50 percentage of CD8+ T-cells Standard Deviation 21	—	—
CD8+ TEM Cells as a Percentage of All CD8+ T-Cells 12-Month Follow-up (N = 4)	51 percentage of CD8+ T-cells Standard Deviation 13	—	—
CD8+ TEM Cells as a Percentage of All CD8+ T-Cells 15-Month Follow-up (N = 3)	46 percentage of CD8+ T-cells Standard Deviation 15	—	—
CD8+ TEM Cells as a Percentage of All CD8+ T-Cells 18-Month Follow-up (N = 3)	46 percentage of CD8+ T-cells Standard Deviation 7	—	—
CD8+ TEM Cells as a Percentage of All CD8+ T-Cells 21-Month Follow-up (N = 21)	46 percentage of CD8+ T-cells Standard Deviation 1	—	—
CD8+ TEM Cells as a Percentage of All CD8+ T-Cells 24-Month Follow-up (N = 3)	33 percentage of CD8+ T-cells Standard Deviation 9	—	—

SECONDARY outcome

Terminally differentiated effector memory T cells are characterized by the cell-surface expression of CD45RA but not CD197 and were analyzed by flow cytometry.

Outcome measures

Outcome measures
Measure	Cohort 1: Blinatumomab 9/28/112 μg/d n=25 Participants Participants received blinatumomab administered via a continuous intravenous infusion (CIV) 9 µg/day for the first week, followed by 28 µg/day for the second week, then 112 µg/day for the remaining 6 weeks of treatment during Cycle 1. Participants who achieved a complete response (CR) or partial response (PR), or had stable disease after the first treatment cycle were eligible to receive a second (consolidation) cycle of treatment over 4 weeks, following a 4-week treatment-free interval.	Cohort 2: Blinatumomab 112 μg/d Participants received blinatumomab CIV at a constant dose of 112 µg/day for 8 weeks of treatment during Cycle 1. Participants who achieved a CR or PR, or had stable disease after the first treatment cycle were eligible to receive a second (consolidation) cycle of treatment over 4 weeks, following a 4-week treatment-free interval.	Cohort 3: Blinatumomab 9/28/112 μg/d Participants received blinatumomab administered CIV 9 µg/day for the first week, followed by 28 µg/day for the second week, then 112 µg/day for the remaining 6 weeks of treatment during Cycle 1. Participants who achieved CR or PR, or had stable disease after the first treatment cycle were eligible to receive a second (consolidation) cycle of treatment over 4 weeks, following a 4-week treatment-free interval.
CD8+ Terminally Differentiated Effector Memory T-cells (TEMRA) Count Screening (N = 25)	0.123 1000 cells/µL Standard Deviation 0.099	—	—
CD8+ Terminally Differentiated Effector Memory T-cells (TEMRA) Count Day 1 Prior (N = 24)	0.072 1000 cells/µL Standard Deviation 0.069	—	—
CD8+ Terminally Differentiated Effector Memory T-cells (TEMRA) Count Day 8 (N = 21)	0.051 1000 cells/µL Standard Deviation 0.042	—	—
CD8+ Terminally Differentiated Effector Memory T-cells (TEMRA) Count Day 15 (N = 16)	0.047 1000 cells/µL Standard Deviation 0.048	—	—
CD8+ Terminally Differentiated Effector Memory T-cells (TEMRA) Count Day 29 (N = 11)	0.058 1000 cells/µL Standard Deviation 0.050	—	—
CD8+ Terminally Differentiated Effector Memory T-cells (TEMRA) Count Day 43 (N = 8)	0.132 1000 cells/µL Standard Deviation 0.126	—	—
CD8+ Terminally Differentiated Effector Memory T-cells (TEMRA) Count End of Infusion (N = 9)	0.135 1000 cells/µL Standard Deviation 0.131	—	—
CD8+ Terminally Differentiated Effector Memory T-cells (TEMRA) Count End of Core Study (N = 6)	0.226 1000 cells/µL Standard Deviation 0.249	—	—
CD8+ Terminally Differentiated Effector Memory T-cells (TEMRA) Count 3-Month Follow-up (N = 5)	0.214 1000 cells/µL Standard Deviation 0.220	—	—
CD8+ Terminally Differentiated Effector Memory T-cells (TEMRA) Count 6-Month Follow-up (N = 6)	0.187 1000 cells/µL Standard Deviation 0.182	—	—
CD8+ Terminally Differentiated Effector Memory T-cells (TEMRA) Count 9-Month Follow-up (N = 4)	0.094 1000 cells/µL Standard Deviation 0.046	—	—
CD8+ Terminally Differentiated Effector Memory T-cells (TEMRA) Count 12-Month Follow-up (N = 4)	0.117 1000 cells/µL Standard Deviation 0.065	—	—
CD8+ Terminally Differentiated Effector Memory T-cells (TEMRA) Count 15-Month Follow-up (N = 3)	0.099 1000 cells/µL Standard Deviation 0.041	—	—
CD8+ Terminally Differentiated Effector Memory T-cells (TEMRA) Count 18-Month Follow-up (N = 3)	0.047 1000 cells/µL Standard Deviation 0.035	—	—
CD8+ Terminally Differentiated Effector Memory T-cells (TEMRA) Count 21-Month Follow-up (N = 21)	0.086 1000 cells/µL Standard Deviation 0.016	—	—
CD8+ Terminally Differentiated Effector Memory T-cells (TEMRA) Count 24-Month Follow-up (N = 3)	0.100 1000 cells/µL Standard Deviation 0.084	—	—

SECONDARY outcome

Terminally differentiated effector memory T cells are characterized by the cell-surface expression of CD45RA but not CD197 and were analyzed by flow cytometry.

Outcome measures

Outcome measures
Measure	Cohort 1: Blinatumomab 9/28/112 μg/d n=25 Participants Participants received blinatumomab administered via a continuous intravenous infusion (CIV) 9 µg/day for the first week, followed by 28 µg/day for the second week, then 112 µg/day for the remaining 6 weeks of treatment during Cycle 1. Participants who achieved a complete response (CR) or partial response (PR), or had stable disease after the first treatment cycle were eligible to receive a second (consolidation) cycle of treatment over 4 weeks, following a 4-week treatment-free interval.	Cohort 2: Blinatumomab 112 μg/d Participants received blinatumomab CIV at a constant dose of 112 µg/day for 8 weeks of treatment during Cycle 1. Participants who achieved a CR or PR, or had stable disease after the first treatment cycle were eligible to receive a second (consolidation) cycle of treatment over 4 weeks, following a 4-week treatment-free interval.	Cohort 3: Blinatumomab 9/28/112 μg/d Participants received blinatumomab administered CIV 9 µg/day for the first week, followed by 28 µg/day for the second week, then 112 µg/day for the remaining 6 weeks of treatment during Cycle 1. Participants who achieved CR or PR, or had stable disease after the first treatment cycle were eligible to receive a second (consolidation) cycle of treatment over 4 weeks, following a 4-week treatment-free interval.
CD8+ TEMRA Cells as a Percentage of All CD8+ T-Cells Screening (N = 25)	41 percentage of CD8+ T-cells Standard Deviation 19	—	—
CD8+ TEMRA Cells as a Percentage of All CD8+ T-Cells Day 1 Prior (N = 24)	39 percentage of CD8+ T-cells Standard Deviation 19	—	—
CD8+ TEMRA Cells as a Percentage of All CD8+ T-Cells Day 8 (N = 21)	36 percentage of CD8+ T-cells Standard Deviation 19	—	—
CD8+ TEMRA Cells as a Percentage of All CD8+ T-Cells Day 15 (N = 16)	46 percentage of CD8+ T-cells Standard Deviation 17	—	—
CD8+ TEMRA Cells as a Percentage of All CD8+ T-Cells Day 29 (N = 11)	34 percentage of CD8+ T-cells Standard Deviation 20	—	—
CD8+ TEMRA Cells as a Percentage of All CD8+ T-Cells Day 43 (N = 8)	39 percentage of CD8+ T-cells Standard Deviation 26	—	—
CD8+ TEMRA Cells as a Percentage of All CD8+ T-Cells End of Infusion (N = 9)	41 percentage of CD8+ T-cells Standard Deviation 24	—	—
CD8+ TEMRA Cells as a Percentage of All CD8+ T-Cells End of Core Study (N = 6)	41 percentage of CD8+ T-cells Standard Deviation 24	—	—
CD8+ TEMRA Cells as a Percentage of All CD8+ T-Cells 3-Month Follow-up (N = 5)	46 percentage of CD8+ T-cells Standard Deviation 26	—	—
CD8+ TEMRA Cells as a Percentage of All CD8+ T-Cells 6-Month Follow-up (N = 6)	41 percentage of CD8+ T-cells Standard Deviation 21	—	—
CD8+ TEMRA Cells as a Percentage of All CD8+ T-Cells 9-Month Follow-up (N = 4)	42 percentage of CD8+ T-cells Standard Deviation 18	—	—
CD8+ TEMRA Cells as a Percentage of All CD8+ T-Cells 12-Month Follow-up (N = 4)	40 percentage of CD8+ T-cells Standard Deviation 15	—	—
CD8+ TEMRA Cells as a Percentage of All CD8+ T-Cells 15-Month Follow-up (N = 3)	46 percentage of CD8+ T-cells Standard Deviation 17	—	—
CD8+ TEMRA Cells as a Percentage of All CD8+ T-Cells 18-Month Follow-up (N = 3)	43 percentage of CD8+ T-cells Standard Deviation 12	—	—
CD8+ TEMRA Cells as a Percentage of All CD8+ T-Cells 21-Month Follow-up (N = 21)	45 percentage of CD8+ T-cells Standard Deviation 3	—	—
CD8+ TEMRA Cells as a Percentage of All CD8+ T-Cells 24-Month Follow-up (N = 3)	51 percentage of CD8+ T-cells Standard Deviation 22	—	—

Adverse Events

Cohort 1: Blinatumomab 9/28/112 µg/d

Serious events: 9 serious events

Other events: 9 other events

Deaths: 0 deaths

Cohort 2: Blinatumomab 112 µg/d

Serious events: 2 serious events

Other events: 2 other events

Deaths: 0 deaths

Cohort 3: Blinatumomab 9/28/112 µg/d

Serious events: 12 serious events

Other events: 14 other events

Deaths: 0 deaths

Cohort 1+3: Blinatumomab 9/28/112µg/d

Serious events: 21 serious events

Other events: 23 other events

Deaths: 0 deaths

Blinatumomab Overall

Serious events: 23 serious events

Other events: 25 other events

Deaths: 0 deaths

Serious adverse events

Serious adverse events
Measure	Cohort 1: Blinatumomab 9/28/112 µg/d n=9 participants at risk Participants received blinatumomab administered CIV 9 µg/day for the first week, followed by 28 µg/day for the second week, then 112 µg/day for the remaining 6 weeks of treatment during Cycle 1. Participants who achieved a CR or PR, or had stable disease after the first treatment cycle were eligible to receive a second (consolidation) cycle of treatment over 4 weeks, following a 4-week treatment-free interval.	Cohort 2: Blinatumomab 112 µg/d n=2 participants at risk Participants received blinatumomab administered CIV at a constant dose of 112 µg/day for 8 weeks of treatment during Cycle 1. Participants who achieved CR or PR, or had stable disease after the first treatment cycle were eligible to receive a second (consolidation) cycle of treatment over 4 weeks, following a 4-week treatment-free interval.	Cohort 3: Blinatumomab 9/28/112 µg/d n=14 participants at risk Participants received blinatumomab administered CIV 9 µg/day for the first week, followed by 28 µg/day for the second week, then 112 µg/day for the remaining 6 weeks of treatment during Cycle 1. Participants who achieved CR or PR, or had stable disease after the first treatment cycle were eligible to receive a second (consolidation) cycle of treatment over 4 weeks, following a 4-week treatment-free interval.	Cohort 1+3: Blinatumomab 9/28/112µg/d n=23 participants at risk Participants received blinatumomab administered CIV 9 µg/day for the first week, followed by 28 µg/day for the second week, then 112 µg/day for the remaining 6 weeks of treatment during Cycle 1. Participants who achieved CR or PR, or had stable disease after the first treatment cycle were eligible to receive a second (consolidation) cycle of treatment over 4 weeks, following a 4-week treatment-free interval.	Blinatumomab Overall n=25 participants at risk All participants who received blinatumomab by continuous intravenous infusion during the core study.
Blood and lymphatic system disorders Agranulocytosis	0.00% 0/9 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	50.0% 1/2 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/14 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/23 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	4.0% 1/25 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Blood and lymphatic system disorders Bone marrow toxicity	0.00% 0/9 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	50.0% 1/2 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/14 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/23 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	4.0% 1/25 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Blood and lymphatic system disorders Neutropenia	0.00% 0/9 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	50.0% 1/2 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/14 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/23 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	4.0% 1/25 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Cardiac disorders Supraventricular tachycardia	11.1% 1/9 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/2 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/14 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	4.3% 1/23 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	4.0% 1/25 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Endocrine disorders Adrenal insufficiency	11.1% 1/9 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/2 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/14 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	4.3% 1/23 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	4.0% 1/25 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Gastrointestinal disorders Oesophagitis	0.00% 0/9 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/2 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	7.1% 1/14 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	4.3% 1/23 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	4.0% 1/25 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
General disorders Disease progression	0.00% 0/9 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/2 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	7.1% 1/14 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	4.3% 1/23 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	4.0% 1/25 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
General disorders Pain	11.1% 1/9 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/2 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/14 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	4.3% 1/23 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	4.0% 1/25 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
General disorders Pyrexia	11.1% 1/9 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	50.0% 1/2 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	14.3% 2/14 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	13.0% 3/23 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	16.0% 4/25 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Infections and infestations Catheter site infection	0.00% 0/9 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/2 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	7.1% 1/14 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	4.3% 1/23 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	4.0% 1/25 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Infections and infestations Device related infection	0.00% 0/9 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/2 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	35.7% 5/14 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	21.7% 5/23 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	20.0% 5/25 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Infections and infestations Herpes virus infection	11.1% 1/9 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/2 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/14 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	4.3% 1/23 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	4.0% 1/25 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Infections and infestations Lobar pneumonia	11.1% 1/9 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/2 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/14 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	4.3% 1/23 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	4.0% 1/25 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Infections and infestations Lung infection	0.00% 0/9 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/2 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	7.1% 1/14 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	4.3% 1/23 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	4.0% 1/25 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Infections and infestations Pneumonia	33.3% 3/9 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	50.0% 1/2 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	14.3% 2/14 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	21.7% 5/23 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	24.0% 6/25 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Infections and infestations Viral infection	11.1% 1/9 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/2 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/14 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	4.3% 1/23 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	4.0% 1/25 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Injury, poisoning and procedural complications Accidental overdose	11.1% 1/9 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/2 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/14 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	4.3% 1/23 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	4.0% 1/25 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Injury, poisoning and procedural complications Drug administration error	0.00% 0/9 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	50.0% 1/2 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/14 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/23 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	4.0% 1/25 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Injury, poisoning and procedural complications Infusion related reaction	11.1% 1/9 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/2 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/14 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	4.3% 1/23 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	4.0% 1/25 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Investigations Pancreatic enzymes increased	0.00% 0/9 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/2 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	7.1% 1/14 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	4.3% 1/23 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	4.0% 1/25 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Metabolism and nutrition disorders Dehydration	0.00% 0/9 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/2 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	7.1% 1/14 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	4.3% 1/23 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	4.0% 1/25 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Musculoskeletal and connective tissue disorders Back pain	0.00% 0/9 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/2 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	7.1% 1/14 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	4.3% 1/23 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	4.0% 1/25 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Musculoskeletal and connective tissue disorders Intervertebral disc protrusion	0.00% 0/9 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/2 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	7.1% 1/14 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	4.3% 1/23 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	4.0% 1/25 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Nervous system disorders Aphasia	22.2% 2/9 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/2 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/14 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	8.7% 2/23 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	8.0% 2/25 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Nervous system disorders Convulsion	0.00% 0/9 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/2 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	7.1% 1/14 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	4.3% 1/23 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	4.0% 1/25 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Nervous system disorders Dizziness	0.00% 0/9 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/2 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	7.1% 1/14 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	4.3% 1/23 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	4.0% 1/25 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Nervous system disorders Encephalopathy	11.1% 1/9 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/2 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	7.1% 1/14 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	8.7% 2/23 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	8.0% 2/25 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Nervous system disorders Epilepsy	0.00% 0/9 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	50.0% 1/2 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/14 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/23 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	4.0% 1/25 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Nervous system disorders Neurological symptom	11.1% 1/9 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	50.0% 1/2 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/14 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	4.3% 1/23 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	8.0% 2/25 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Nervous system disorders Speech disorder	11.1% 1/9 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	50.0% 1/2 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/14 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	4.3% 1/23 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	8.0% 2/25 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Nervous system disorders Syncope	0.00% 0/9 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/2 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	7.1% 1/14 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	4.3% 1/23 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	4.0% 1/25 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Nervous system disorders Tremor	11.1% 1/9 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/2 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/14 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	4.3% 1/23 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	4.0% 1/25 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Respiratory, thoracic and mediastinal disorders Pleurisy	11.1% 1/9 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/2 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/14 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	4.3% 1/23 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	4.0% 1/25 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Respiratory, thoracic and mediastinal disorders Pulmonary embolism	11.1% 1/9 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/2 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/14 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	4.3% 1/23 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	4.0% 1/25 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Respiratory, thoracic and mediastinal disorders Respiratory failure	0.00% 0/9 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	50.0% 1/2 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/14 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/23 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	4.0% 1/25 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Vascular disorders Deep vein thrombosis	22.2% 2/9 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/2 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/14 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	8.7% 2/23 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	8.0% 2/25 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.

Other adverse events

Other adverse events
Measure	Cohort 1: Blinatumomab 9/28/112 µg/d n=9 participants at risk Participants received blinatumomab administered CIV 9 µg/day for the first week, followed by 28 µg/day for the second week, then 112 µg/day for the remaining 6 weeks of treatment during Cycle 1. Participants who achieved a CR or PR, or had stable disease after the first treatment cycle were eligible to receive a second (consolidation) cycle of treatment over 4 weeks, following a 4-week treatment-free interval.	Cohort 2: Blinatumomab 112 µg/d n=2 participants at risk Participants received blinatumomab administered CIV at a constant dose of 112 µg/day for 8 weeks of treatment during Cycle 1. Participants who achieved CR or PR, or had stable disease after the first treatment cycle were eligible to receive a second (consolidation) cycle of treatment over 4 weeks, following a 4-week treatment-free interval.	Cohort 3: Blinatumomab 9/28/112 µg/d n=14 participants at risk Participants received blinatumomab administered CIV 9 µg/day for the first week, followed by 28 µg/day for the second week, then 112 µg/day for the remaining 6 weeks of treatment during Cycle 1. Participants who achieved CR or PR, or had stable disease after the first treatment cycle were eligible to receive a second (consolidation) cycle of treatment over 4 weeks, following a 4-week treatment-free interval.	Cohort 1+3: Blinatumomab 9/28/112µg/d n=23 participants at risk Participants received blinatumomab administered CIV 9 µg/day for the first week, followed by 28 µg/day for the second week, then 112 µg/day for the remaining 6 weeks of treatment during Cycle 1. Participants who achieved CR or PR, or had stable disease after the first treatment cycle were eligible to receive a second (consolidation) cycle of treatment over 4 weeks, following a 4-week treatment-free interval.	Blinatumomab Overall n=25 participants at risk All participants who received blinatumomab by continuous intravenous infusion during the core study.
Blood and lymphatic system disorders Anaemia	0.00% 0/9 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	50.0% 1/2 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	7.1% 1/14 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	4.3% 1/23 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	8.0% 2/25 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Blood and lymphatic system disorders Leukopenia	11.1% 1/9 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/2 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	21.4% 3/14 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	17.4% 4/23 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	16.0% 4/25 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Blood and lymphatic system disorders Neutropenia	0.00% 0/9 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/2 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	7.1% 1/14 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	4.3% 1/23 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	4.0% 1/25 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Blood and lymphatic system disorders Thrombocytopenia	11.1% 1/9 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/2 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	28.6% 4/14 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	21.7% 5/23 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	20.0% 5/25 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Cardiac disorders Arrhythmia	0.00% 0/9 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	50.0% 1/2 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/14 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/23 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	4.0% 1/25 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Cardiac disorders Cardiac failure	11.1% 1/9 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/2 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/14 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	4.3% 1/23 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	4.0% 1/25 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Cardiac disorders Cardiovascular insufficiency	0.00% 0/9 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/2 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	7.1% 1/14 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	4.3% 1/23 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	4.0% 1/25 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Cardiac disorders Tachycardia	11.1% 1/9 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/2 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/14 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	4.3% 1/23 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	4.0% 1/25 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Ear and labyrinth disorders Deafness	11.1% 1/9 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/2 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/14 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	4.3% 1/23 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	4.0% 1/25 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Ear and labyrinth disorders Vertigo	22.2% 2/9 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/2 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/14 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	8.7% 2/23 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	8.0% 2/25 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Eye disorders Blepharospasm	0.00% 0/9 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/2 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	7.1% 1/14 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	4.3% 1/23 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	4.0% 1/25 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Eye disorders Keratitis	11.1% 1/9 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/2 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/14 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	4.3% 1/23 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	4.0% 1/25 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Eye disorders Visual acuity reduced	0.00% 0/9 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/2 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	7.1% 1/14 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	4.3% 1/23 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	4.0% 1/25 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Gastrointestinal disorders Abdominal discomfort	11.1% 1/9 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/2 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/14 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	4.3% 1/23 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	4.0% 1/25 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Gastrointestinal disorders Abdominal pain	0.00% 0/9 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/2 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	7.1% 1/14 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	4.3% 1/23 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	4.0% 1/25 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Gastrointestinal disorders Aphthous stomatitis	11.1% 1/9 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/2 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/14 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	4.3% 1/23 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	4.0% 1/25 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Gastrointestinal disorders Constipation	11.1% 1/9 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/2 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/14 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	4.3% 1/23 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	4.0% 1/25 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Gastrointestinal disorders Diarrhoea	44.4% 4/9 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	50.0% 1/2 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	7.1% 1/14 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	21.7% 5/23 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	24.0% 6/25 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Gastrointestinal disorders Dyspepsia	11.1% 1/9 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/2 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/14 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	4.3% 1/23 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	4.0% 1/25 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Gastrointestinal disorders Flatulence	0.00% 0/9 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/2 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	14.3% 2/14 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	8.7% 2/23 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	8.0% 2/25 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Gastrointestinal disorders Gastrointestinal motility disorder	0.00% 0/9 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/2 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	7.1% 1/14 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	4.3% 1/23 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	4.0% 1/25 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Gastrointestinal disorders Mouth ulceration	0.00% 0/9 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/2 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	7.1% 1/14 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	4.3% 1/23 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	4.0% 1/25 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Gastrointestinal disorders Nausea	11.1% 1/9 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/2 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/14 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	4.3% 1/23 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	4.0% 1/25 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Gastrointestinal disorders Odynophagia	11.1% 1/9 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/2 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/14 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	4.3% 1/23 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	4.0% 1/25 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Gastrointestinal disorders Vomiting	0.00% 0/9 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/2 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	7.1% 1/14 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	4.3% 1/23 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	4.0% 1/25 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
General disorders Asthenia	11.1% 1/9 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/2 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/14 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	4.3% 1/23 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	4.0% 1/25 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
General disorders Catheter site erythema	0.00% 0/9 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/2 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	7.1% 1/14 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	4.3% 1/23 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	4.0% 1/25 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
General disorders Catheter site rash	0.00% 0/9 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/2 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	7.1% 1/14 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	4.3% 1/23 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	4.0% 1/25 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
General disorders Chills	11.1% 1/9 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/2 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	14.3% 2/14 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	13.0% 3/23 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	12.0% 3/25 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
General disorders Disease progression	0.00% 0/9 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/2 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	21.4% 3/14 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	13.0% 3/23 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	12.0% 3/25 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
General disorders Facial pain	0.00% 0/9 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/2 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	7.1% 1/14 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	4.3% 1/23 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	4.0% 1/25 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
General disorders Fatigue	33.3% 3/9 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	50.0% 1/2 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	21.4% 3/14 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	26.1% 6/23 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	28.0% 7/25 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
General disorders General physical health deterioration	11.1% 1/9 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/2 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/14 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	4.3% 1/23 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	4.0% 1/25 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
General disorders Mucosal inflammation	11.1% 1/9 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/2 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/14 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	4.3% 1/23 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	4.0% 1/25 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
General disorders Oedema	11.1% 1/9 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/2 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	35.7% 5/14 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	26.1% 6/23 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	24.0% 6/25 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
General disorders Oedema peripheral	0.00% 0/9 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/2 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	7.1% 1/14 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	4.3% 1/23 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	4.0% 1/25 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
General disorders Pain	0.00% 0/9 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/2 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	7.1% 1/14 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	4.3% 1/23 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	4.0% 1/25 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
General disorders Pyrexia	44.4% 4/9 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	50.0% 1/2 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	35.7% 5/14 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	39.1% 9/23 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	40.0% 10/25 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
General disorders Ulcer	11.1% 1/9 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/2 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/14 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	4.3% 1/23 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	4.0% 1/25 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Hepatobiliary disorders Jaundice	0.00% 0/9 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/2 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	7.1% 1/14 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	4.3% 1/23 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	4.0% 1/25 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Immune system disorders Drug hypersensitivity	11.1% 1/9 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	50.0% 1/2 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/14 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	4.3% 1/23 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	8.0% 2/25 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Infections and infestations Bronchitis	11.1% 1/9 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/2 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/14 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	4.3% 1/23 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	4.0% 1/25 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Infections and infestations Candida infection	22.2% 2/9 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/2 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/14 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	8.7% 2/23 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	8.0% 2/25 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Infections and infestations Candiduria	0.00% 0/9 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/2 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	7.1% 1/14 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	4.3% 1/23 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	4.0% 1/25 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Infections and infestations Conjunctivitis	0.00% 0/9 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/2 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	7.1% 1/14 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	4.3% 1/23 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	4.0% 1/25 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Infections and infestations Diverticulitis	11.1% 1/9 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/2 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/14 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	4.3% 1/23 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	4.0% 1/25 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Infections and infestations Fungal infection	11.1% 1/9 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	50.0% 1/2 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/14 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	4.3% 1/23 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	8.0% 2/25 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Infections and infestations Herpes simplex	11.1% 1/9 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/2 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/14 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	4.3% 1/23 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	4.0% 1/25 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Infections and infestations Infection	0.00% 0/9 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/2 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	7.1% 1/14 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	4.3% 1/23 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	4.0% 1/25 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Infections and infestations Nasopharyngitis	0.00% 0/9 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/2 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	21.4% 3/14 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	13.0% 3/23 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	12.0% 3/25 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Infections and infestations Otitis media	11.1% 1/9 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/2 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/14 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	4.3% 1/23 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	4.0% 1/25 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Infections and infestations Pneumonia	11.1% 1/9 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/2 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	7.1% 1/14 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	8.7% 2/23 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	8.0% 2/25 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Infections and infestations Respiratory tract infection	11.1% 1/9 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/2 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/14 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	4.3% 1/23 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	4.0% 1/25 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Infections and infestations Rhinitis	11.1% 1/9 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/2 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/14 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	4.3% 1/23 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	4.0% 1/25 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Infections and infestations Urinary tract infection	0.00% 0/9 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/2 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	7.1% 1/14 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	4.3% 1/23 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	4.0% 1/25 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Infections and infestations Vulvovaginal candidiasis	11.1% 1/9 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/2 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/14 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	4.3% 1/23 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	4.0% 1/25 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Injury, poisoning and procedural complications Spinal compression fracture	11.1% 1/9 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/2 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/14 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	4.3% 1/23 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	4.0% 1/25 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Investigations Antithrombin III decreased	0.00% 0/9 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/2 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	7.1% 1/14 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	4.3% 1/23 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	4.0% 1/25 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Renal and urinary disorders Renal failure	0.00% 0/9 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	50.0% 1/2 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/14 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/23 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	4.0% 1/25 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Investigations Blood fibrinogen increased	0.00% 0/9 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/2 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	7.1% 1/14 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	4.3% 1/23 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	4.0% 1/25 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Investigations Blood glucose increased	0.00% 0/9 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/2 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	28.6% 4/14 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	17.4% 4/23 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	16.0% 4/25 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Investigations Blood immunoglobulin G decreased	22.2% 2/9 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/2 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/14 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	8.7% 2/23 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	8.0% 2/25 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Investigations Blood lactate dehydrogenase increased	11.1% 1/9 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/2 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/14 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	4.3% 1/23 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	4.0% 1/25 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Investigations Blood magnesium decreased	11.1% 1/9 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/2 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/14 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	4.3% 1/23 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	4.0% 1/25 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Investigations Blood potassium decreased	0.00% 0/9 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/2 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	7.1% 1/14 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	4.3% 1/23 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	4.0% 1/25 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Investigations Blood sodium decreased	11.1% 1/9 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/2 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/14 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	4.3% 1/23 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	4.0% 1/25 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Investigations Blood uric acid increased	0.00% 0/9 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/2 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	7.1% 1/14 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	4.3% 1/23 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	4.0% 1/25 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Investigations C-reactive protein increased	11.1% 1/9 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/2 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	21.4% 3/14 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	17.4% 4/23 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	16.0% 4/25 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Investigations Corneal reflex decreased	0.00% 0/9 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/2 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	7.1% 1/14 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	4.3% 1/23 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	4.0% 1/25 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Investigations Fibrin D dimer increased	11.1% 1/9 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/2 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	7.1% 1/14 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	8.7% 2/23 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	8.0% 2/25 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Investigations Fibrinolysis increased	11.1% 1/9 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/2 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/14 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	4.3% 1/23 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	4.0% 1/25 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Investigations Gamma-glutamyltransferase increased	0.00% 0/9 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/2 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	7.1% 1/14 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	4.3% 1/23 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	4.0% 1/25 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Investigations Hepatic enzyme increased	0.00% 0/9 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/2 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	7.1% 1/14 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	4.3% 1/23 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	4.0% 1/25 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Investigations Neutrophil count decreased	0.00% 0/9 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/2 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	7.1% 1/14 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	4.3% 1/23 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	4.0% 1/25 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Investigations PO2 decreased	11.1% 1/9 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/2 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/14 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	4.3% 1/23 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	4.0% 1/25 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Investigations Platelet count decreased	0.00% 0/9 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	50.0% 1/2 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	7.1% 1/14 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	4.3% 1/23 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	8.0% 2/25 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Investigations Weight increased	0.00% 0/9 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/2 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	21.4% 3/14 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	13.0% 3/23 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	12.0% 3/25 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Investigations White blood cell count decreased	0.00% 0/9 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	50.0% 1/2 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	7.1% 1/14 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	4.3% 1/23 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	8.0% 2/25 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Metabolism and nutrition disorders Diabetes mellitus	11.1% 1/9 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/2 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/14 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	4.3% 1/23 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	4.0% 1/25 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Metabolism and nutrition disorders Hyperglycaemia	22.2% 2/9 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	50.0% 1/2 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	14.3% 2/14 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	17.4% 4/23 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	20.0% 5/25 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Metabolism and nutrition disorders Hypocalcaemia	0.00% 0/9 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	50.0% 1/2 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/14 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/23 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	4.0% 1/25 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Metabolism and nutrition disorders Hypokalaemia	11.1% 1/9 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/2 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	21.4% 3/14 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	17.4% 4/23 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	16.0% 4/25 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Metabolism and nutrition disorders Vitamin K deficiency	11.1% 1/9 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/2 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/14 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	4.3% 1/23 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	4.0% 1/25 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Musculoskeletal and connective tissue disorders Back pain	11.1% 1/9 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/2 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	14.3% 2/14 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	13.0% 3/23 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	12.0% 3/25 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Musculoskeletal and connective tissue disorders Bone pain	0.00% 0/9 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/2 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	7.1% 1/14 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	4.3% 1/23 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	4.0% 1/25 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Musculoskeletal and connective tissue disorders Intervertebral disc protrusion	11.1% 1/9 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/2 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/14 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	4.3% 1/23 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	4.0% 1/25 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Musculoskeletal and connective tissue disorders Muscular weakness	22.2% 2/9 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	50.0% 1/2 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/14 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	8.7% 2/23 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	12.0% 3/25 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Musculoskeletal and connective tissue disorders Musculoskeletal pain	0.00% 0/9 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/2 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	7.1% 1/14 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	4.3% 1/23 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	4.0% 1/25 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Musculoskeletal and connective tissue disorders Myopathy	11.1% 1/9 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/2 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/14 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	4.3% 1/23 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	4.0% 1/25 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Musculoskeletal and connective tissue disorders Neck pain	0.00% 0/9 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/2 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	7.1% 1/14 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	4.3% 1/23 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	4.0% 1/25 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Musculoskeletal and connective tissue disorders Pain in extremity	0.00% 0/9 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/2 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	7.1% 1/14 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	4.3% 1/23 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	4.0% 1/25 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Neoplasm progression	0.00% 0/9 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/2 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	7.1% 1/14 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	4.3% 1/23 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	4.0% 1/25 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Oncologic complication	0.00% 0/9 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/2 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	7.1% 1/14 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	4.3% 1/23 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	4.0% 1/25 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Tumour pain	0.00% 0/9 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/2 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	7.1% 1/14 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	4.3% 1/23 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	4.0% 1/25 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Nervous system disorders Ataxia	11.1% 1/9 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/2 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/14 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	4.3% 1/23 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	4.0% 1/25 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Nervous system disorders Burning sensation	0.00% 0/9 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/2 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	7.1% 1/14 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	4.3% 1/23 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	4.0% 1/25 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Nervous system disorders Coordination abnormal	0.00% 0/9 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	50.0% 1/2 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/14 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/23 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	4.0% 1/25 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Nervous system disorders Dizziness	11.1% 1/9 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/2 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	7.1% 1/14 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	8.7% 2/23 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	8.0% 2/25 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Nervous system disorders Dyscalculia	11.1% 1/9 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/2 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/14 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	4.3% 1/23 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	4.0% 1/25 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Nervous system disorders Dysgeusia	0.00% 0/9 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/2 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	7.1% 1/14 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	4.3% 1/23 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	4.0% 1/25 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Nervous system disorders Encephalopathy	0.00% 0/9 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/2 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	7.1% 1/14 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	4.3% 1/23 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	4.0% 1/25 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Nervous system disorders Epilepsy	11.1% 1/9 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/2 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/14 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	4.3% 1/23 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	4.0% 1/25 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Nervous system disorders Facial paresis	0.00% 0/9 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/2 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	7.1% 1/14 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	4.3% 1/23 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	4.0% 1/25 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Nervous system disorders Headache	11.1% 1/9 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/2 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/14 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	4.3% 1/23 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	4.0% 1/25 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Nervous system disorders Hyporeflexia	0.00% 0/9 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	50.0% 1/2 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/14 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/23 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	4.0% 1/25 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Nervous system disorders Memory impairment	11.1% 1/9 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/2 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/14 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	4.3% 1/23 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	4.0% 1/25 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Nervous system disorders Paraesthesia	11.1% 1/9 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/2 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	7.1% 1/14 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	8.7% 2/23 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	8.0% 2/25 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Nervous system disorders Radiculopathy	0.00% 0/9 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/2 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	7.1% 1/14 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	4.3% 1/23 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	4.0% 1/25 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Nervous system disorders Sensory disturbance	0.00% 0/9 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/2 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	7.1% 1/14 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	4.3% 1/23 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	4.0% 1/25 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Nervous system disorders Somnolence	22.2% 2/9 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/2 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/14 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	8.7% 2/23 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	8.0% 2/25 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Nervous system disorders Speech disorder	33.3% 3/9 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	50.0% 1/2 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/14 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	13.0% 3/23 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	16.0% 4/25 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Nervous system disorders Tremor	66.7% 6/9 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	100.0% 2/2 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	28.6% 4/14 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	43.5% 10/23 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	48.0% 12/25 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Nervous system disorders Vocal cord paralysis	11.1% 1/9 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/2 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/14 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	4.3% 1/23 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	4.0% 1/25 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Psychiatric disorders Confusional state	11.1% 1/9 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/2 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	7.1% 1/14 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	8.7% 2/23 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	8.0% 2/25 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Psychiatric disorders Disorientation	22.2% 2/9 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	50.0% 1/2 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/14 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	8.7% 2/23 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	12.0% 3/25 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Psychiatric disorders Encopresis	11.1% 1/9 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/2 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/14 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	4.3% 1/23 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	4.0% 1/25 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Psychiatric disorders Fear	0.00% 0/9 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/2 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	7.1% 1/14 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	4.3% 1/23 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	4.0% 1/25 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Psychiatric disorders Insomnia	0.00% 0/9 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/2 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	14.3% 2/14 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	8.7% 2/23 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	8.0% 2/25 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Psychiatric disorders Nervousness	0.00% 0/9 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/2 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	7.1% 1/14 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	4.3% 1/23 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	4.0% 1/25 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Psychiatric disorders Sleep disorder	0.00% 0/9 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/2 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	14.3% 2/14 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	8.7% 2/23 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	8.0% 2/25 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Renal and urinary disorders Enuresis	22.2% 2/9 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/2 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/14 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	8.7% 2/23 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	8.0% 2/25 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Renal and urinary disorders Haematuria	22.2% 2/9 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/2 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/14 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	8.7% 2/23 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	8.0% 2/25 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Renal and urinary disorders Ureteric obstruction	0.00% 0/9 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/2 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	7.1% 1/14 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	4.3% 1/23 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	4.0% 1/25 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Renal and urinary disorders Urinary retention	0.00% 0/9 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/2 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	7.1% 1/14 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	4.3% 1/23 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	4.0% 1/25 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Respiratory, thoracic and mediastinal disorders Cough	33.3% 3/9 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	50.0% 1/2 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	7.1% 1/14 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	17.4% 4/23 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	20.0% 5/25 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Respiratory, thoracic and mediastinal disorders Dysphonia	0.00% 0/9 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/2 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	7.1% 1/14 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	4.3% 1/23 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	4.0% 1/25 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Respiratory, thoracic and mediastinal disorders Dyspnoea	0.00% 0/9 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/2 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	7.1% 1/14 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	4.3% 1/23 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	4.0% 1/25 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Respiratory, thoracic and mediastinal disorders Nasal disorder	11.1% 1/9 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/2 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/14 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	4.3% 1/23 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	4.0% 1/25 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Respiratory, thoracic and mediastinal disorders Pleural effusion	11.1% 1/9 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/2 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/14 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	4.3% 1/23 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	4.0% 1/25 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Respiratory, thoracic and mediastinal disorders Pulmonary congestion	11.1% 1/9 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/2 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/14 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	4.3% 1/23 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	4.0% 1/25 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Respiratory, thoracic and mediastinal disorders Pulmonary embolism	0.00% 0/9 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/2 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	7.1% 1/14 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	4.3% 1/23 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	4.0% 1/25 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Respiratory, thoracic and mediastinal disorders Rhinorrhoea	11.1% 1/9 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/2 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/14 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	4.3% 1/23 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	4.0% 1/25 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Respiratory, thoracic and mediastinal disorders Tachypnoea	11.1% 1/9 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/2 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/14 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	4.3% 1/23 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	4.0% 1/25 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Skin and subcutaneous tissue disorders Dermatitis allergic	0.00% 0/9 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	50.0% 1/2 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/14 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/23 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	4.0% 1/25 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Skin and subcutaneous tissue disorders Drug eruption	11.1% 1/9 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/2 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/14 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	4.3% 1/23 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	4.0% 1/25 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Skin and subcutaneous tissue disorders Eczema asteatotic	11.1% 1/9 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/2 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/14 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	4.3% 1/23 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	4.0% 1/25 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Skin and subcutaneous tissue disorders Hyperhidrosis	11.1% 1/9 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/2 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	14.3% 2/14 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	13.0% 3/23 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	12.0% 3/25 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Skin and subcutaneous tissue disorders Night sweats	11.1% 1/9 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/2 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	14.3% 2/14 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	13.0% 3/23 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	12.0% 3/25 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Skin and subcutaneous tissue disorders Rash	11.1% 1/9 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/2 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/14 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	4.3% 1/23 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	4.0% 1/25 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Skin and subcutaneous tissue disorders Skin ulcer	0.00% 0/9 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/2 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	7.1% 1/14 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	4.3% 1/23 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	4.0% 1/25 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Vascular disorders Embolism	11.1% 1/9 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/2 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/14 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	4.3% 1/23 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	4.0% 1/25 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Vascular disorders Haematoma	11.1% 1/9 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/2 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/14 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	4.3% 1/23 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	4.0% 1/25 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Vascular disorders Hypotension	11.1% 1/9 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/2 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/14 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	4.3% 1/23 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	4.0% 1/25 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.
Vascular disorders Thrombosis	0.00% 0/9 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	0.00% 0/2 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	7.1% 1/14 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	4.3% 1/23 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.	4.0% 1/25 • From the first dose of blinatumomab until up to 30 days after the last dose, until the data cut-off date of 10 July 2014; the overall median duration of treatment exposure was 46.8 days. Adverse Events were not pre-specified to be monitored/assessed after 10 July 2014. Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.

Additional Information

Study Director

Amgen, Inc.

Phone: 866-572-6436

Results disclosure agreements

Principal investigator is a sponsor employee The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.
Publication restrictions are in place

Restriction type: OTHER